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PREFACE 
The purpose of this thesis is to evaluate profits 
in the ethical drug industry. A lot has been said and writ-
ten about profits in the past and more will be said in the 
future. It is natural for the Soviet Union to denounce our 
profit system, but the word "profit" is not the most popular 
one in the most capitalistic country in the world: the 
United States of America. 
Since profits have become so controversial, it will 
be one of the author's intention to analyze what profits 
have done to the ethical drug industry. Are the profits in 
the ethical drug industry too high? If so, why are they 
high? Is there a monopoly in the industry which keeps prices 
high? These are some of the questions that will be examined. 
The author has an interest in the ethical drug in-
dustry since he is working for a leading pharmaceutical com-
pany. He has had experience in detailing and while carrying 
out this function, he has talked to hundreds of doctors 
about drugs, profits, and the well-being of people. This 
experience will surely be of great help in writing the the-
sis. 
The assistance of Professor Carson is acknowledged 
here. Without his deep interest in students, the thesis 
would not have been completed. 
ix 
CHAPTER I 
HISTORY OF THE DRUG INDUSTRY 
AN UNKNOWN INDUSTRY--INTRODUCTION 
Until the widely publicized hearings in 1959 and 
1960 before the Subcommittee on Antitrust and Monopoly head-
ed by Estes Kefauver, the outside world accepted the drug 
industry for what it appeared to be, an 11 adjunct 11 of the med-
ical profession. It came as a shock to most people to read 
that the drug industry was in business, like most companies 
in a free enterprise system, for one reason: to ~ a 
profit. 
FUNCTION OF THE INDUSTRY 
This industry, unlike other industries, owes its 
existence to the misery of mankind; for without sickness 
there would be no ethical drug industry to speak of. 
What is the function of the pharmaceutical indus-
try? This industry is devoted to the development, manufac-
ture, promotion, and sale of medicines for prescription of 
physicians or for sale direct to the public. 
Today there are about 1,300 companies in the in-
dustry of which 28 companies exceed sales of $8,000,000 a 
year. 1 These 28 companies account for almost 90% of all 
drug sales in the United States. 
1 
INVESTIGATION OF THE DRUG INDUSTRY 
One of the reasons for investigating the drug in-
dustry was to determine whether there existed a monopoly in 
the industry and whether the prices for drugs were "admin-
istered prices." As early as 1957 "evidence of possible 
price fixing irregularities in the drug industry came before 
Congress in 1957 in a report by the House Government Opera-
tions Intergovernmental Relations Subcommittee on activities 
of the Department of Health Education and Welfare relating 
to polio vaccine."2 This, however, is not the first time 
that the drug industry was under fire. As early as 1934, it 
was charged that the drug industry "has advocated restraint 
of price cutting more consistently than any other group."3 
The widely publicized hearings have resulted in a 
greater interest on part of the public about the drug indus-
try. The ethical drug industry, too, is awakening and seems 
to take the warning of Prof. Blackmann seriously that there 
is a "paucity of readily available information on any contin-
uous basis."4 More data is being made available to interest-
ed parties, and a public advertising campaign has been 
launched recently. 
In order to gain a better understanding of the in-
dustry, the author will review briefly the history of the 
ethical drug industry. 
BEGINNING OF THE U. S. DRUG INDUSTRY 
For thousands of years, man has used herbs and 
2 
plant products to help himself when he was ill. The most 
ancient medical formulary in the world is supposed to be the 
Papyrus Ebers, which is believed to have been compiled some-
where around 1500 B.c.5 "Three hundred and ninety-five 
years ago, a Pharmacopoeia Augustava listing 1,100 medicinal 
agents was published."6 The number has increased to 30,000 
by now. 
DEVELOPMENT OF THE U. S. DRUG INDUSTRY 
The development of the U. s. drug industry has been 
quite phenomenal. It changed from the peddler-type who made 
and sold his "pill for everything" to a $2,500,000,000 indus-
try which employs thousands of people. The ethical drug in-
dustry has helped to increase the life expectancy of the 
average American to the highest level in the world. It has 
developed effective drugs (more than 20 drugs in use for 
heart diseases; 15 major steriods now in use for inflamma-
tory diseases and many others) that cure diseases which kill-
ed many people each year. On the other hand, however, there 
are those who claim that some drug companies have gone so 
far that "even new disease states have been invented to en-
courage the use of some drugs."7 
The William S. Merrell Company is considered to be 
the oldest pharmaceutical company in the United States.8 
The firm was established in 1828. In the following 60 years, 
some of today•s giants were born: Parke-Davis in 1866, 
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Upjohn in 1886 and Abbott in 1888. These houses were estab-
lished because doctors were dissatisfied.with the uniformity 
and effectiveness of available medicines. 
THE DOCTOR OWNED-COMPANY 
The first doctor to set up his own company was Dr. 
Upjohn in Kalamazoo, Michigan. He was followed by Dr. Abbott 
in Chicago. Doctors would carry in their bags the drugs 
made by the doctors (Abbott and Upjohn). When business in-
creased, the kitchen laboratories became too small and fac-
tories were needed. As the distribution moved to the drug-
stores, doctors would specify in their prescription, for 
example, Dr. Upjohn's drugs. As doctor-founded companies 
came out with new products, they would "spread the word 
among doctors."9 Since most practitioners did not have the 
facilities and time to do research and make their own drugs, 
and since the makers of pharmaceuticals came to them with 
detailed data and samples of the product, the system appealed 
to doctors. The system has more or less gained the force of 
law among physicians over the years. 
Three other factors are worth mentioning concern-
ing this period. (1) During the Civil War, drugs moved 
from a local to a national level because troops were scat-
tered all over the country. (2) In 1906, the Food and Drug 
Act was passed which prohibited certain medicine from being 
sold without prescription. (3) "At the turn of the century, 
4 
the synthetic organic chemical industry began to grow in im-
portance."10 
WORLD WAR I AND WORLD WAR II ITS EFFECT ON THE INDUSTRY 
Much of the modern knowledge of drugs has been 
gained since the beginning of the 20th Century. The great-
est growth, however, of the United States drug industry has 
taken place in an atmosphere of national emergency. 
WORLD WAR I 
Up until World War I, world production of medici-
nal chemicals was centered in Germany. Since World War I, 
"our weakness in things pertaining to materia medica was 
blatantly held up to public notice."11 The United States 
lacked not only the special know how, but also the scientists 
of the various diciplines. This lack had never been noti·ced 
before since almost all synthetic compounds were imported 
from Germany. When the United States declared war on Ger-
many in 1917, all imports ceased. 
"The industry (U.S.) started in desperation from 
a standstill, marshaled homegrown talent, and by heroic ef-
fort cracked some of the synthesizing techniques the Germans 
had kept so secret."12 
Although the industry had grown to independence at 
the end of the war, it had not yet come of age. German drug 
companies again set up affiliates in the United States after 
the war, but did not regain the virtual monopoly they had 
5 
before. 
WORLD WAR II 
Before the outbreak of World War II, sales of the 
drug industry ran between $200 and $300 million. 13 However, 
during this war, the drug industry made the greatest progress 
yet. Among the important developments were penicillin and 
new drugs for tropical diseases. Most of the work had been 
done on behalf of the government for the armed forces. Over 
"200,000,000 shots of serum1114 were administered to American 
fighting men. 
Until the mid 1940's, the drug industry consisted 
or four leaders: Abbott, Lilly, Upjohn, and Parke-Davis. 
Since vastly expanded capacity was required, and since many 
companies realized that it was much more profitable to formu-
late and merchandise drugs themselves, Merck, Pfizer, and 
Lederle, which had produced fine chemicals, entered the pre-
scription field. 
At the end of the war, there were "ninety-two 
plants in the medicinal chemical industry as contrasted with 
only ten establishments before World War II."15 The number 
of employees increased :rrom 111,802 before the war to 9,414 
in 1947. "16 
With the war over, the pharmaceutical companies 
had to intensify their search for new products since the 
armed forces sharply cut their drug purchases. 
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1945-1961 - "THE GOLDEN AGE" 
After the war, pharmaceutical manufacturers in-
creased their investments in extremely costly scientific re-
search and development programs. Since then, new antibio-
tics have been developed with a potency undreamed of only a 
few years ago. The discovery and marketing of such "wonder 
drugs" as steriods, antihistamines, tranquilizers and oral 
diabetic drugs have turned ethical drug production into a 
major industry. Unlike before, the United States now became 
a source of new inventions and discoveries and the leading 
pharmaceutical exporter of the world. As we can see from 
the following chart, exports have risen sharply while imports 
remained virtually the same. 
CHART I 
EXPORTS VS. IMPORTS OF DRUGS 
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"Drug Industry •• Filling Prescriptions Under 
Fire," Business Week, (No. 1632; December 
10,1960), p. 143. 
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RISE OF PROFITS 
The years after the war have not only witnessed a 
tremendous increase in new products, and thus sales, but also 
in profits that were twice as high as in any other industry. 
As a result of the high rewards, new companies have entered 
the field which has resulted in increased competition and 
increased expenditures for research and promotion. Since 
the sales to profit ratio still remains at 12%, charges have 
been made in regard to "administered prices" and "unreason-
able profits." As mentioned before, the industry received 
unfavorable publicity in the late 50's and early 6o•s. 
Earnings did go down somewhat as a result, but preliminary 
figures for 1962 show that the ethical drug industry has en-
tered the "golden age" again. 
In the following chapter, the author will examine 
those aspects of the ethical drug industry which make the 
industry so unique. 
8 
follows: 
CHAPTER II 
UNDERSTANDING THE DRUG INDUSTRY 
TYPES OF PHARMACEUTICAL COMPANIES 
The ethical drug industry can be classified as 
{1) "~ ~ Houses offer their own speci-
alties and most package sizes of almost 
every competitive item. 
(2) Short ~ Houses offer just their spe-
cialties. 
(3) Competitive Houses offer only competi-
tive items which they might put out under 
a trade name • ttl 7 Competitive s can be 
manufactured and sold by any drug company 
since there is no patent coverage. 
A more meaningful way of classifying drug compa-
nies was given by John T. Connor of Merck & Company before 
the Kefauver Subconunittee on Antitrust and Monopoly: 
(1) "The creators, those companies that do the 
expensive work of developing new drugs."18 
Companies in this group are the life 
blood of the industry because without 
the development of new drugs, there would 
be no growth for the ethical drug indus-
try. 
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{2) "Molecule Manipulator. The research 
budget of these companies is just enough 
to bring out competitives once the crea-
tive companies have shown the way. 
(3) The Coat-Tail Riders. Companies in this 
classification conduct no research at 
all."19 They wait until a market for a 
new product is established and then com-
pound it cheaply. This is especially 
the case when the new product has not 
yet been patented. 
Following is a table which shows clearly to what 
extent the coat-tail riders can underbid creators. 
TABLE I 
PREDNISONE 5 MILLIGRAM TABLETS IN BOTTLES OF 100 
WHOLESALE PRICE TO THE DRUGGISTS IN THE U.S.A. 
SIZE PRICE 
COMPANY (SALES PER YEAR) PER 100 TABLETS 
MERCK OVER $200,000,000 $17.90 
UP JOHN 100 to 150,000,000 17.90 
SCHERING 50 to 100,000,000 17.90 
U.S. VITAMIN & PHARM. CO. 10 to 50,000,000 9.33 
PHYSICIANS DRUG & SUPPLY 1 to 5,000,000 4.00 
BRYANT 250 to 1,000,000 6.75 
LAMMETT 100 to 250,000 12.00 
PENHURST UNDER 100,000 6.95 
PREMO (bid to government) 
-------- 2.35 
Source: David C. Coyle, How To Get Safe Dr s and Cut Their 
Costs, {Washington, D.C.: Public Affairs Institute , 
p. 4. 
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THE TWO C1S - THE ONLY ALTERNATIVE? 
During the drug investigations, it was often 
pointed out by those speaking against the "creators," that 
these companies will "charge what the market will bear." 
We shall see later whether it is true. At any rate, it was 
said that the compounders and coat-tail riders are the only 
alternative to the high priced creators. While the author 
admits that the difference between high and the low bid is 
tremendous, we must keep the following important factors in 
mind. 
(1) The two C1 s (Compounders and Coat-tail 
riders) are not interested in basic research. If every com-
pany had such an attitude, we would still be where we were 
one hundred years ago. The conclusion is simple; there 
would be no progress. 
(2) The two C's do not stock a complete line 
of pharmaceuticals. These companies stock only the fastest 
moving items. However, in the interest of public health, it 
is necessary to stock items that are not in big demand, but 
which can be life savers when they are needed. This func-
tion again is handled only by the old line reputable compa-
nies. 
(3) There is a real quality problem with the 
C's. Tests by the Food and ~Administration showed that 
there is a difference in quality of drugs between creative 
11 
makers and the two C's. "Only 1/20 of 1% of the samples 
(8,376) examined from the leading companies were subject to 
legal actions. However, six per cent of the samples {8,621) 
taken from 1,200 companies doing 13% of the ethical business 
were found to be below standard."20 
PROPRIETARY VS. ETHICAL DRUGS 
THE PROPRIETARY DRUG INDUSTRY 
Americans spent $5.3 billion on drugs and sundries 
in 1960.21 Approximately 30% of each year's total goes for 
proprietary preparations. 
A proprietary product is a medicinal or curative 
packaged product sold under a brand name and extensively 
promoted for direct consumer purchase. Doctors have told 
the author that they are not friends of proprietary compa-
nies because these companies practice "medicine" via tele-
vision and radio. The doctors, as a result, lose business. 
The leading proprietary company is American Home 
Products with such leading products as Dristan and Anacin. 
Bristol-Myers, Richardson-Merrell and Carter Products are 
other top-ranked companies. In recent years the ethical as 
well as proprietary companies have cut into each others' 
field. Proprietary companies are getting into the ethical 
field because that's where the money is. Net income as a 
percentage of sales for 1961 for the ten leading proprietary 
companies (American Home Products, Bristol-Myers, Oarter 
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Products, Mead Johnson, Miles Laboratory, Norwich Pharmaceu-
ticals, Plough, Richardson-Merrell, Sterling, and Warner-
Lambert) was "~ as compared to 13.4% for the ten leading 
ethical drug producers"22 which are Abbott, Lilly, Merck, 
Parke-Davis, Pfizer, Schering, Searle, Smith Kline and French, 
u. S. Vitamins and Upjohn. Observers of the drug industry 
blame the dependence on advertisihg for the lower earnings 
of the former group. Another reason why proprietary compa-
nies are getting into the ethical field is the fact that ex-
tensive government regulation of "over the counter" proprie-
tary items limits sales growth. 
ETHICAL DRUGS 
Ethical drugs, in contrast to proprietary drugs, 
can only be obtained on a prescription basis. Advertising 
is not directed to the consumer, but rather to the person 
who has the power of decision over the prescription drugs: 
the doctor. 
There is an increasing tendency on the part of the 
ethical companies to enter the proprietary field through ac-
quisitions or through newly formed divisions. In fact, four 
of the top ten ethical companies are already in the proprie-
tary field. With diversification the "theme" of most Ameri-
can companies, this trend seems bound to increase even more 
in the future. 
13 
STEPS INVOLVED IN THE DEVELOPMENT OF A DRUG 
Developing a new ethical drug is extremely diffi-
cult. In 1958, for example, "the industry's laboratories 
worked with 114,600 different chemical substances."23 Out 
24 
of these substances came only "40 new drugs." The "risk 
ratio" was 2,865 to !.· As can be seen from these figures, 
the odds to synthesize a new product are very high. With 
this risk ratio in mind, let us now examine the steps in-
volved in the development of a new drug. 
THE DEVELOPMENT OF A NEW DRUG 
(1) The chemistry department within a company's 
researoh division analyzes compounds. If one of the hundreds 
of compounds analyzed should show any promise of being worth-
while to study further, a larger quantity of the compound 
will be made up, which in turn will be put in a dosage form. 
(2) The biology department will now take over and 
study the effects of the new compound on the body. To deter-
mine whether the agent is suitable for trial on human beings, 
toxity tests are first conducted on animals. In 1961 alone, 
nine million animals were used for such tests. Among others, 
"5.7 million mice, 2.2 million rats, and 739,000 chickens."25 
If research is to proceed, testing of drugs in hu-
mans must at some point be carried out. Should the tests in 
small number of humans be successful, the clinical department 
will administer and supervise a clinical trial on a large 
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scale. Often up to five years have elapsed since the com-
pound was chosen as a potential drug. The next step is to 
submit all the data gathered so far to the FDA (Food and 
Drug Administration) for further evaluation and approval. 
Only when the agency has approved the new drug can the mar-
keting process begin. 
What channels of distribution are used to get this 
new drug to the ultimate user? This question will be an-
swered in the following section. 
CHANNELS OF DISTRIBUTION 
The following diagram shows the way drugs are usu-
ally distributed. 
MAKER 
WHOLESALERS 
...... Get price discount 
about 2~ on 
volume orders 
DRUGSTORES 
Get 3~ - 40% 
markup on most 
items 
DOCTORS 
Sometimes dispense 
drugs themselves 
on which they ask 30% price discount 
Some companies such as Lilly sell only to wholesalers. In 
fact, they have an exclusive agreement with the Na~onal 
Wholesale Druggists' Association which has 335 members. 
Lilly agrees not to sell directly to retailers, and the 
~holesalers agree to buy competitive items only from Lilly. 
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Most other large companies sell to wholesalers as well as to 
retailers. As far as the dispensing doctors are concerned, 
they are usually' located in low income areas. The dis-
pensing physician charges between $6 to $8 per visit in-
cluding drugs. The overall cost for the patient is reduced 
because the doctor usually buys drugs by generic name and 
the markup for the wholesaler and retailer is saved. 
From personal experience the author would say that 
no more than five to ten per cent of the physicians are dis-
pensing. If one could convince more doctors to dispense 
drugs, this would be a great step toward reducing the cost of 
medical care. 
THE DETAILMAN 
A detailman is a person employed in the drug in-
dustry to help promote ethical pharmaceuticals. Unlike his 
counterpart in other industries, the salesman, the detailman 
creates demand for the products by promoting the drug to the 
doctor who may then prescribe the pharmaceuticals. In other 
words the detailman will neither appeal to the wholesaler 
and druggist nor to the consumer to help him sell his drugs. 
Salaries and expenses are estimated between $10,000 
and $12,000 annually. Since there are an estimated 15,000 
detailmen in the drug industry, the total bill is almost 
"$200 million a year."26 
THE RIGHT HAND MAN 
A survey among doctors sponsored by the American 
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Medical Association showed that "68% of the responding doc-
tors indicated that the detailman is the best source for in-
formation on new product data."27 Despite the fact that the 
average cost per doctor call is about $6.55,9ompanies that 
had only relied on journal advertising in the past are now 
using detailmen too because of their effectiveness. Although 
critics of the drug industry have called the detailmen "door 
to door peddlers," the author having been a detailman himself 
for six months disagrees with this statement. No drug can 
accomplish anything until doctors know about it. The profes-
sional service representative links the manufacturer and the 
doctor and is indispensable. 
THE "CAPTIVE" CONSUMER 
The ethical drUg industry is probably the only in-
dustry which does not advertise directly to the consumer. 
It is established practice to advertise only to the pre-
scribing physician. All other means are considered "uneth-
ical." Since the patient can not shop around for drugs but 
must buy what the doctor prescribes, one can call him a 
"captive consumer. 11 A person who has to pay for something 
over which he has no choice often rebels. The author be-
lieves that this was one of the reasons why Senator Kefauver 
had such a tremendous public support during his investigation 
of the ethical drug industry. 
THE ACTIVE CONSUMER 
Many doctors have told me recently that the so-
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called "captive consumer" has become "overactive" in the 
sense that he is actually telling the doctor what medicine 
he wants. Doctors attribute this mainly to Readers' Digest 
which often carries articles on drugs. To what extent this 
will change the "captive consumer" to one who has a choice 
over what he has to take can not yet be estimated. Since 
Readers' Disest has not yet explained the price advantages of 
generic name drugs, it is believed that the magazine really 
does not do a service to the "captive consumer." 
SUPPLY AND DEMAND AS APPLIED TO THE DRUG INDUSTRY 
Economists say that the price of a product usually 
depends on: 
(1) The cost of production 
(2) The product's usefulness 
(3) The magnitude of the demand 28 
Cost of production plays only a small factor in 
determining the price. The product's usefulness is of greater 
importance. The price of a product is usually high when doc-
tor and patient have waited for such a particular drug. 
Merrell's anti-cholestoral drug, the first such drug on the 
market, is such an example. 
THE DEMAND FOR A DRUG 
The magnitude of the demand, however, is the most 
important factor. As Francis Brown, president of Sobering, 
told members of the Kefauver Committee "unlike consumer mar-
keting, Schering can not expand its markets by lowering 
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prices."29 As a result, companies figure in advance what 
the potential market is for the drug and then set a price. 
They must, as we will see later, recuperate their heavy re-
search costs as fast as possible. Competition will sooner 
or later come out with a similar drug which will force the 
first company to lower its price. 
In summary, the demand for a drug can not be cre-
ated, it is already established even before the drug has been 
discovered. Demand, as the economist would say, is inelas-
tic. 
Having now gained some understanding of the eth-
ical drug industry, let us proceed to the consumer health 
bill. 
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CHAPTER III 
THE CONSUMER HEALTH BILL 
MEDICAL CARE AND THE PEOPLE'S MONEY 
Although the total expenditures for medical care 
amounted only to "4.9% in 1956 and 5.8% in 1961 of personal 
disposable income,"3° this relatively small percentage is 
probably the most controversial item of all personal expend-
itures. Whl? To understand the people's feelings, let us 
examine the nations' expenditures for medical care. 
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Source: "Health Insurance •• Why Spending Is Soaring," 
Business Week, {No. 1660; June 24, 1961), p. 145. 
Medical News Magazine, World of Medicine, 
fVol. VII; No. 1, January, 1963), p. 83. 
As we can see from Chart II, the cost of medical care has 
risen sharply over the past 13 years. In fact the increase 
amounted to over 85%. It ·is true that income after taxes 
and purchasing power has gone up too, but the real complaint 
is that medical care has gone up faster than any other item 
of the family budget. 
Between 1960 and 1962 alone, the cost of medical 
care went up from "108.1 (1957 to 1959 = 100%) to 114.9 in 
October of 1962. The consumer price index rose only from 
103.1 to 106.0 during the same time."31 In other words a 
5.9% increase for medical care vs. a 2.7% increase for con-
sumer prices. 
Having looked at the chart which shows statistics 
over a thirteen year period and the latest figures available 
from the U. s. Department of Commerce, let us now examine 
the parties who make up the "medical care team." 
THE HOSPITAL RATES 
In defending those who make up the medical care 
team, it should be said that numbers tell nothing about the 
quality of the medical care Americans are getting. 
Hospital care has been vastly improved and the 
latest machines contribute greatly to the well-being of the 
average patient. However, the author doubts seriously whether 
there is a justification in tripling hospital rates over the 
last thirteen years. Having come from a country which orig-
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inated social security, the author must admit that there is 
a great waste in the American system. Every small hamlet 
wants a hospital of its own. This in itself is perfectly 
acceptable1 but what the author criticizes is the large 
amount of duplication of extremely expensive machines. If 
X hospital would take care of all patients with Y disease in 
the area, the other hospitals would not have to buy the same 
machines too. Great savings and probably lower hospital 
rates would be incurred. 
DOCTORS 1 FEES 
As we can see from the following chart, the doctors• 
fees have increased 67% in the last thirteen years. 
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Business Week, {No. 1660; June 24, 1961), 
p. 146. 
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Dr. Adenauer, Chancellor of West Germany, in a re-
cent hour long talk over NBC TV called American physicians 
a closed corporation. To an extent, this is true because 
the supply of new medical students is controlled by the Amer-
ican Medical Association. The law of supply and demand has 
a real meaning here, because the reason why fees are so high 
and are rising is due to the scarcity of doctors. Since doc-
tors probably have the most costly and most effective lobby 
in Washington, some time will pass before this profession 
will be investigated. 
The smallest price increase occurred in the third 
member of the medical care team: drugs. The increase amount-
ed to ~in thirteen years. This is actually~ less than 
the increase in the consumer price index. A more thorough 
analysis of drug prices will follow in the following chapter 
on profits. 
From this brief analysis of the consumer health 
bill, we have seen that the drug industry was not entirely 
to blame for the large increase in the cost of medical care. 
Had this been made clearer during the Kefauver hearings on 
the drug industry, the author is sure that the public and 
press would not have had quite the ill feelings about the in-
dustry. 
In the following chapter the author will come to 
the heart of the thesis: the profits of the ethical drug 
industry. 
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11Nothing contributes as much to 
the prosperity and happiness of 
a country as high profits. 11 
David Ricardo 
1820 
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CHAPTER IV 
PROFITS AND THE ETHICAL DRUG INDUSTRY 
Profits are excess revenues over applicable ex-
penses. This definition sounds simple, but is it really 
that easy to determine what a company earns? According to 
Claude Robinson: "No one can lmow for sure what a business 
earns over its lifetime until it is liquidated."32 In order 
then to determine profits, the accountant must assume first 
the going concern principle; the assumption is that business 
will continue from year to year. A reasonably accurate re-
port can be rendered if prices have remained fairly stable 
over an extended period. 
PROFITS AND PROFITEERS 
Assuming that we have been able to determine prof-
its for a company, what does the public think about profits? 
Franklin D. Roosevelt called those who owned or controlled big 
companies "economic royalists" and "princes of profits."33 
President J. F. Kennedy called those who wanted to increase 
steel prices 11 irresponsible." In a recent survey, 40% of 
those people interviewed ranging from professionals to union 
members felt that American corporations were making too much 
money! Are u. s. enterprises still profiteering enterprises? 
"Over the past ten years National Income has almost doubled, 
but corporate profits after taxes actually amounted to $22.7 
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billion in 1960 as against $22.8 billion in 1950."34 The 
rate of economic growth also declined and unemployment in-
creased during this time. It is the author's belief that 
the life blood of the free enterprise system is adequate 
profits. Without an adequate level, the economy will have 
troubles growing, because there may not be the incentive to 
invest in new projects or there may even be a lack of funds. 
PROFITS, PROFITS, PROFITS 
A company in a free enterprise system is 11 very 
largely concerned to maximize the money margin between cost 
inputs and their revenue output."35 One of the best tests of 
economic effectiveness is the profit level a company achieves. 
Because profits are such an effective test, some companies, 
at times, do not employ the most ethical means to reach 
their goal. 
"Administered prices 11 is a relatively new term in 
our .American word treasure. They are "those (prices} set 
without regard to supply and demand by a few large companies 
holding a large share of the market."36 Every corporation 
that was studied by Business Week showed a certain amount of 
"administered prices in the sense that most companies deter-
mine prices in advance of production, basing it on cost cal-
culations and market prospects."37 
Since there is a heavy concentration in many of our 
industries, such power can be misused to make what Senator 
Kefauver called "unreasonable profits." Since none of us 
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think alike, everybody has a different idea of what reason-
able or unreasonable profits are. However, standards of com-
parisons can be employed which will help in the evaluation 
of profits. 
STANDARDS OF COMPARISON 
As we have seen in the preceding pages, it is very 
difficult to measure profits. It is also difficult to de-
termine what standards of comparisons are proper for a partic-
ular company or industry. For example, it was charged that 
"drugs marketed by Schering were marked up as much as 
700CJ%."38 A close analysis revealed that selling costs were 
not included! Net income after taxes as a per cent of sales 
is in the author 1 s opinion the standard that can be applied 
with fairness to any company or industry, because companies 
are in business to sell goods or services at a certain price 
above cost. At the end of the year (or whenever there is a 
need for it} the accountant will make up an income statement. 
To see how effective and efficient the company had operated, 
the first and last item on the income statement will be com-
pared. This is what will be done now. 
NET INCOME AFTER TAXES AS A PERCENTAGE OF SALES 
The following table shows net income as a percent-
age of sales for a number of industries which were selected 
by the author because of their concentration. In each indus-
try the top three companies are shown. 
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TABLE II 
NET INCOME AFTER TAXES 
AS A PERCENTAGE OF SALES - 1960 
NAME OF % PROFIT INDUSTRY 
INDUSTRY COMPANY ON SALES AVERAGE 
Cement 12.4 
Ideal 13.7 
Lone Star 13.9 
Lehigh Portland 9.6 
Chemicals 11.8 
Du Pont 11.6 
Union Carbide 10.2 
Eastman Kodak 13.5 
Business 6.5 
Machines 
I. B. M. 11.7 
Sperry Rand 3.2 
National Cash Register 4.4 
Autos and 
Trucks 5.6 
General Motors 7.5 
Ford 8.2 
Chrysler 1.1 
Drugs 11.0 
Lilly 10.5 
Pfizer 9.7 
Merck 12.8 
Source: Claude Robinson, Understanding Profits, (Prince-
town{ New Jersey: Van Nostrand Company, Inc., 
1961), p. 474-482. 
The industries shown above have as much and even 
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more concentration among the top three companies than the 
ethical drug industry. There is no doubt that companies 
with a certain control over the market sometimes use this 
influence to charge prices which they would not charge under 
conditions if a single company did. not have an appreciable 
portion of the market. 
To demonstrate what control over the market means, 
note Table I in Chapter II on page 11. Three of the leading 
companies in the industry have the same wholesale price for 
PREDNISONE, a drug for arthritis. These are the companies 
that have a large number of detailmen and are in daily con-
tact with doctors. Since the average doctor does not even 
know that the companies with the lower bids exist , he can 
not write for their brand of PREDNISONE. As we will see in 
the next chapter, there are often cross licenses between 
leading firms for certain products. If there is an agree-
ment to sell the other company's product under a different 
brand name, there usually is no price competition between 
these companies. The company which can best talk the doctor 
into using his brand will get the greater share of the mar-
ket. 
A PROFITABLE INDUSTRY 
The following chart will give a greater insight 
into the ethical industry. The figures of eleven leading 
companies were combined to arrive at the industry average. 
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The chart reveals that up until the time of the drug investi-
gation in 1959, net income as a percentage of sales for the 
industry had gone up ever since 1952. The highest level, 
14.6%, was reached in 1958, up from 10.1% in 1952. The 14.6% 
figure is almost 2! times as high as the average for all in-
dustries. However, there has been a downward trend since 
the 1958 high to a preliminary figure of 12.1% for 1962. 
Jo 
/'I 
,, 
/I{ 
'" 
CHART IV 
NET INCOME AS A PERCENTAGE OF SALES 
ETHICAL DRUG INDUSTRY 1952-1961 
. .-;._.,.~. 
30 
~9s'~----,,•5•3--•11•~·~--,·,~s.~S~/~9S~,~~,~95~7~·,~9~S~8--I~9~SY~~/9~{,~~~1~9£~1~/~~~~JX 
Source: Figures were computed by the author from the 
following sources: (1) Standard & Poors, 
Drugs, Cosmetics, {Vol. no. not given{ Section 
4~ndustry Survey, December 20, 1962), p. D-6. (2) Standard & Poors, "Drugs, Basic Analysis," 
Drugs, Cosmetics, (Vol. no. not given; Section 
2, December 13, l9b2), p. D-20. 
X: Computed from nine months figures since full 
year figures are not yet available. 
Having evaluated profits according to the standard 
considered most meaningful, it is clear that the ethical 
drug industry is very profitable. In 1961, "return on sales 
for!!! pharmaceuticals was 10.5%."39 This put the ethical 
drug industry in second place of all industries. 
What is the industry's return on operating income? 
The following pages will answer this question. 
OPERATING INCOME AS A PERCENTAGE OF SALES 
Before the data is introduced, let us define its 
meaning. Operating income usually is the balance left from 
sales after deducting operating costs, selling, general and 
administrative expenses; local and state taxes; provision 
for bad debts and pensions. Depreciation charges and feder-
al taxes are not yet deducted. 
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Source: Standard & Poors, "Drugs, Basic Analysis," 
Drugs, Cosmetics, (December 13, 1962, 
Section 2), p. D-20. 
{Data compiled by the author from figures supplied by 
Standard & Poors) 
As Chart V reveals, an all-time industry high of 
30% was reached in 1957. From 1957 until 1960 there was a 
decline of about 2~ although this trend was reversed in 
1961 when operating income as a percentage of sales was 26.2%. 
As in preceding charts, the wonder drug companies G. D. Searle 
and Smith, Kline & French inflated the industry average. 
Searle had a return of 49.5~ and Smith, Kline & French a re-
turn of 34.9 % over a ten-year period. 
The profit margin of the ethical drug industry is 
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probably the highest of all industries., Only Gillette can 
be ranked ahead of all ethical companies except for G. D. 
Searle when it comes to evaluating operating income as a 
percentage of sales. 
In evaluating profits of an industry, the analyst 
should never be satisfied with one or two standards of com-
parisons. That is why the author will now look at the re-
turn on invested capital. 
RETURN ON INVESTED CA.f!TAL 
Return on invested capital can not be applied to 
all industries because some industries have large investments 
in fixed assets, whereas other industries need not have 
large sums invested. For example, a retail store with an in-
vestment of $150,000 and a consulting firm with an invest-
ment of $12,000 may both have net sales of $600,000 per year 
with a profit of $30,000, or 5% of net sales in each case. 
If the return is expressed in terms of invested capital, the 
former would have a rate of return of 20% and ~ for the 
consulting firm. This comparison would have no real meaning. 
While the ethical drug industry employs capital, 
it is not used to the extent as in the steel or automotive 
industry. The ethical drug industry invests heavily in sci-
entists. As we will see later, there are four times as many 
scientists in this industry as in any other industry. There-
fore, while the following comparison will help to demonstrate 
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the profitability of the industry the preceding discussion 
should be kept in mind. 
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CHART VI 
RETURN ON INVESTED CAPITAL 
PERCENTAGE OF SALES 1952-1961 
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Source: Figures computed by the author from sales 
and capital data supplied by: 
Standard & Poors, "Basic Anallsis," Dr~s, 
Cosmetics, (December 13, 1962), p. D-1~ 
ANALYSIS OF THE RATE OF RETURN 
Here again we see that there was an almost embar-
rassing rate of return as related to capital. Again we see 
a decline, however, this time it starts as early as 1956. 
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Two reasons can be cited. (1) Heavy capital expenditures 
beginning in the mid 50's both here and abroad. (2) The 
adverse effects of the Kefauver hearings probably made com-
panies think twice. By this I mean, instead of showing high 
returns some of the money was put into capital expenditures. 
Having worked in the finance section of one of the leading 
companies in the United States, (while this particular com-
pany was under fire for price fixing) the author witnessed 
the procedure explained above. When a company does not want 
to show excess profits for a period, the money can be put 
into a reserve account (bad debt, future contigencies, etc.) 
or the building program can be accelerated. 
Rate of return on capital ranges from a 235% re-
turn for Smith, Kline & French in 1952 to 9.9% for Merck in 
1959. Some companies such as G. D. Searle and Smith, Kline 
& French have shown a consistently high return averaging 
56.1% over a ten-year period for the former and 50.3% for the 
latter. Old line houses such as Abbott and Parke-Davis 
"only" showed a 19.2% return and 20.4% return respectively. 
It is the author's opinion that the difference is due to the 
fact that Searle and Smith, Kline & French are relatively 
new companies and that their period of growth is just start-
ing which will force them to have heavier capital layouts 
very soon. 
How does the average compare with other industries? 
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According to Drug and Cosmetic Industry Magazine, the ethi-
cal drug industry led all other industries on return of in-
vested capital in 1961. 
COMPANIES WITH SUSTAINED MARGINS 
In two major standards of comparisons, it has been 
shown that the drug business is profitable. In order to get 
the truest picture possible about the ethical drug industry, 
the following table may help the reader. The table shows 
how many drug companies are among the top fifty companies 
with the "best well-kept-up margins" despite a profit 
squeeze in recent years. 
TABLE III 
RATE OF RETURN ON SALES 1958-1961 
POSITION AMONG 5C 
NAME OF COMPANIES WITH A YEAR 
COMPANY WELL-KEPT-UP 
PROFIT MARGIN 1958 1959 1960 1961 
G. D. Searle 5 21.4 21.2 20.3 22.2 
Up john 11 13.8 14.8 14.3 13.8 
u. s. Vitamin 12 12.5 13.4 14.1 13.6 
Norwich 
Pharmaceutical 14 11.7 12.7 13.2 13.2 
Sterling Drug 23 9.7 10.0 10.2 10.2 
Bristol Myers 36 6.2 6.6 7.2 7.8 
Baxter 
Laboratories 47 5.6 6.3 5.9 6.3 
Source: Mood~'s Stock Survey, (Vol. LIV; No. 51, December 
17,1 62), p. 263. 
{Figures compiled bf the author from 50 companies 
shown in Moody's) 
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To the credit or discredit of the drug industry, there are 
seven drug companies that are among the top fifty firms with 
the best sustained profit margin during the past four years. 
In fact, over 25% of the top fifteen companies with the great-
est ability to resist a profit squeeze belong to the drug 
industry! 
PROFITABLE -- WHY? 
Searle is presently the only company with an oral 
contraceptive drug. Sales are presently over $22 million on 
this drug alone, and quite profitable too since the company 
still enjoys a monopolistic position. Upjohn, on the other 
hand, also has a virtual monopoly in the oral diabetic mar-
ket. A drug called ORINASE, which was introduced in 1957, 
is the only effective drug on the market so far. These two 
products are probably the reason why these two companies 
have had such outstanding profit margins over the past few 
years. 
So far we have seen that the profits of the ethi-
cal drug industry are quite high. Since the public pays the 
price for the high drugs, how do 15,000,000 individuals, the 
investing public, view the industry? 
THE INVESTING PUBLIC AND PROFITS OF THE ETHICAL DRUG INDUSTRY 
In the following chart the author computed the 
high and low of the price earning ratios for the industry. 
High 11 price earnings ratios" are usually associated with 
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growth industries. The ethical drug industry is not only a 
growth industry, but at the same time has offered the inves-
tors relatively high stable dividends. 
'lo 
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CHART VII 
PRICE EARNING RATIOS OF THE ETHICAL DRUG INDUSTRY 
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Source: Figures compiled by the author from data supplied 
by: 
Standard & Poors' Industry Survey, 
(December 13, 1962), p. D-21. 
THE TREND 
The chart shows a very interesting trend. Up until 
the time of the drug investigation, there was no significant 
difference in the price earning ratio of the ethical drug 
industry and that of the rest of the industries. Then, des-
pite a slight decrease in profits for the following two years 
in the ethical drug industry, more inv~stors than ever be-
fore realized that this industry gave them what they wanted: 
outstanding growth and excellent earnings. As a result, 
stock prices of the drug companies have gone up while prices 
of companies in the other industries have remained relative-
ly stable. 
FUNDED DEBT AND DIVIDENDS 
Of the eleven leading companies with sales totaling 
over $1.6 billion in 1961, the funded debt was only $40 mil-
lion of which $25 million or 6~ belonged to Pfizer. In 
other words, the tremendous expansion (sales were $960 mil-
lion in 1952 as compared to $1.6 billion in 1961) was financed 
mostly from funds generated from within. Companies claim 
that they need above average profits to pay for the expan-
sion, but critics say that outside financing rather than in-
ternal funds should be used to finance expansion. The 
author, too, feels that the funded debt of the ethical drug 
industry is unusually small; and rather than increase prices 
of drugs to finance expansion, more funds from the "outside" 
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should be employed. 
DIVIDEND POLICY 
While the industry has been able to get along with 
a small amount of debt despite the huge expansion, they 
were also able to pay out a large percentage of the earnings 
per common share. In the following chart a comparison is 
made between "the common dividends as a percentage of earn-
ings per common share" for the drug industry and the rest 
of the industries. 
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Ratios for the ethical drug industry were 
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Standard & Poors. 
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While there is no significant difference in the 
percentage payout of earnings per share, it should be remem-
bered that the ethical drug industry was able to pay rela-
tively high and stable dividends. "(Abbottsince 1926, Merck 
since 1935, Lilly since 1885, Pfizer since 1901, Parke-Davis 
since 1878, Upjohn since 1909)"40 while undertaking a very 
costly expansion program without incurring large sums of 
short and long term debts. How can this be done? Only 
through earnings well above average. 
STOCK RATINGS 
Stock ratings, too, are quite significant in eval-
uating the profits of an industry. Standard and Poors' 
ratings are.based on "stability and growth of earnings; and 
stability, growth, and security of dividends. There are 31 
drug companies listed by Standard & Poors of which 26 have a 
rating of A-, A, or A+. "Of all industries listed, only the 
electric utilities have a similar top rating."4l 
RATE EARNED ON COMMON STOCKHOLDERS' EQUITY 
There are other standards of comparisons that can 
be used. Two more will be mentioned. "Rate earned on com-
mon stockholders' equity," sometimes referred to as "finan-
cial ratio" is calculated by dividing net income after taxes 
and after preferred dividend requirements by the equity of 
the common stockholders. The rate earned is above average 
since the industry's net income is extremely high and pre-
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ferred dividend requirements as we shall see are very low. 
TIMES PREFERRED DIVIDEND REQUIREMENTS EARNED 
The last indicator, ability of a company to meet 
dividend requirements, is indicated in the following table. 
TABLE IV 
TIMES PREFERRED DIVIDEND REQUIREMENTS EARNED 
COMPANY 1961 1960 
Baxter 16 14 
Lilly 346 296 
Merck 73 74 
Abbott NONE NONE 
Parke-Davis NONE NONE 
Pfizer (Chas.) NONE NONE 
Schering 23 22 
Searle NONE NONE 
Smith, Kline & French NONE NONE 
Up john NONE NONE 
An interpretation of the figures shows that most 
companies do not even issue preferred stock. Preferred 
stock, at times, is issued when additional capital is re-
quired. As we have seen before, ethical drug companies have 
financed most of the expansion out of internal funds. Those 
companies that did issue preferred stock have the dividend 
requirements covered from 14 to 349 times. This, by itself, 
is another indicator of the profitability of ethical drug 
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companies if compared to companies in other industries. 
Before a final conclusion is reached, an evaluation 
of the leading ethical houses will be made. 
AN EVALUATION OF LEADING PHARMACEUTICAL COMPANIES 
Companies in the ethical drug industry are not as 
large as those in other industries. In fact, Fortune listed 
not a single pharmaceutical company among the 100 largest 
companies in its latest survey. This is really not impor-
tant; what is most significant is that these companies are 
one of the most profitable of any industry. 
Following is a discussion of the leading ethical 
producers, which account for over 40% of ethical drug sales. 
The other 60% of sales is distributed among 1,300 other com-
panies. 
ABBOTT LABORATORIES 
Abbott produces about 550 items including antibio-
tics, antihistaminic agents, hormones, sulfonamides, vita-
mins, and many other drugs. Since its founding in 1888, it 
has climbed to a prominent position in the ethical drug 
field. 
Of the 1961 sales of $129,850,090, "50% of the in-
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come came from products introduced in the past eight years." 
While the company's growth and profit margins are below in-
dustry average, heavy research expenditures (1960-$8,200,000, 
1961 - $9,600,000) will insure that the company will continue 
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to grow. 
ELI LILLY 
Eli Lilly is a leading producer of pharmaceuticals 
biological, and antibiotic drug products. The company makes 
over 1,000 items which are distributed solely through whole-
salers. 
Research and development expenditures amounted to 
about $130,000,000 between 1952 to 1961. 
The company is the third largest ethical firm in 
the United States, and it was one of the few companies in 
the industry to report record earnings for 1962. Following 
are some "vital" statistics. 
ELI LILLY COMPANY 
r INCOME EARNINGS RESEARCH & 
YEAR NET SALES NET INCOME OF SALES PER SHARE DEVELOPMENT 
1961 $198,117,689 $23, 075, 67~ 11.6 2.88 $20,165,000 
1960 178,548,121 18,751, 57E 10.5 2.34 19,717,000 
1959 187,010,259 23,445, 75r 12.5 2.93 18,313,000 
1955 141,316,999 16,328,08 11.6 2.12 N.A. 
Note: Earnings per share $3.20 in 1962 
Source: Figures compiled by the author from the following 
sources: 
(1) "Weekly Technical Comments." E.F. Hutton & Co. 
(No volume number given; February 21, 1963). 
(2) 
(3) 
Standard & Poors, Basic Analysis, (December 
13,1962), p. D-20. 
Standard & Poors, Standard Corporation Des-
cri¥tions,{Vol. XXIII; No. 25, Section 2, 
Sep ember, 1962), p. 6865. 
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As we can see from the figures, earnings are high 
but can change fast. In 1960, income was down by $5 million 
from 1959 because the demand for polio vaccines had decreased. 
In 1961, sales had increased $21 million over 1960, yet due 
to a profit squeeze and adverse publicity of the industry, 
net income was still lower than in 1959. Tears, however, 
should not be shed because the company's rate of return was 
still twice as high as the average for all industries. 
MERCK & COMPANY, INC. 
Merck, the second largest ethical drug company, 
not only sells to wholesalers and retailers but also to 
other manufacturers, and in 80 countries of the free world. 
Leading product groups in 1961 were steriods, hor-
mones, and diuretics. Total sales amounted to $228 million 
in 1961. Net income was $27,190,000 or 11.9% of sales. 
Although Merck has not grown as fast as Pfizer, (Merck sales 
in 1952 were $160 million vs. Pfizer's sales $107 million) 
the company, however, has not only shown a higher rate of re-
turn but has invested much more money than Pfizer in re-
search. ($60 million for Merck vs. $40,000,000 for research 
for Pfizer from 1959 to 1961). 
PARKE-DAVI§ &,C.OMEJNY 
Parke-Davis is one of the most diversified ethical 
concerns in the country with some 500 different items. Phar-
maceuticals, antibiotics, biologicals are some of the dif-
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ferent product categories. 
With a consistently high rate of return and divi-
dends paid since 1878, the company has been a favorite of 
investors up until 1961. Like Lilly, Parke-Davis had a prob-
lem with its leading money maker: CHLOROMYCETIN. Because 
of the reported side effects, doctors turned away from the 
drug. Company·sales dropped to $184 million in 1961 from 
$200,000,000 in 1960 and net income decreased from $30 mil-
lion in 1960 to $22 million in 1961. Net income was 15.2% 
in 1960 and "only" 12.1% in 1961 of sales. 
With total research expenditures of $25,000,000 
for 1960 and 1961, there is no doubt that this company will 
regain its place as one of the most profitable companies in 
the industry. 
PFIZER (CHAS.) & COMPANY 
Pfizer is presently the largest company in the 
ethical drug field. Sales in 1961 totaled over $312 million, 
up from $107 million in 1952. This company is without doubt 
the fastest growing and at the same time most controversial 
in the field. Its very aggressive promotion and advertising 
campaign has often been criticized. The campaign apparently 
is successful since sales continue to grow fast as we can 
see from the following statistics. 
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PFIZER (CHAS.) & COMPANY 
~T INCOME EARNINGS 
YEAR NET SALES NFJ.' INCOME ~ OF SALES PER SHARE RESEARCH 
1961 $312,433,262 $31,442,905 10.1 $1.74 $13,555,000 
1960 289,762,291 28,248,150 9.7 1.58 13,427,000 
1959 253,672,721 24,862,955 9.8 1.5) . 13,682,000 
Source: Standard & Poors, Standard Corporation Des-
criptions, (Vol. XXIII; No. 20, Section 2, 
June -July, 1962), p. 5746-5747. 
Pfizer's rate of return is below the industry average, prob-
ably due to the very large research and capital expenditures, 
which amounted to $110 million since 1959!' The heavy re-
search expenditures are already paying off. Nine-month fig-
ures for 1962 showed net income up 13% over 1961. 
SMITH, KLINE & FRENCH 
Smith, Kline & French develops, produces, and sells 
ethical pharmaceutical specialties. Tranquilizers, antihis-
tamines, amphetamines, and anti-spasmodics are some of the 
areas of specialization. 
Following is a breakdown of important company sta-
tistics. 
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SMITH, KLINE & FRENCH 
~T INCOME EARNINGS RESEARCH & 
YEAR NET SALES NET INCOME ~ OF SALES PER SHARE DEVELOPMENT 
1961$161,161,726 $27,072,865 16.8 $1.85 $14,274,000 
1960 147,987,335 24,390,916 16.5 1.67 13,651,000 
1959 134,890,663 25,005,738 18.5 1.72 12,100,000 
Source: Standard & Poors, Standard Corporation Des-
criptions, (Vol. XXIII; No. 20, Section 2, 
June - July, 1962), p. 6006. 
Smith, Kline & French not only increased its sales by over 
10% in each of the last three years, but unlike other fast 
growing companies was able to maintain the second highest 
rate of return in the ethical drug industry. Tranquilizers 
have helped in achieving this position • 
Profitability in 1962 apparently kept up because 
"the quarterly dividend was increased to 30¢ from 25¢ in 
1961 and a year end extra of 30¢ from 25¢ in 1961."43 
According to Standard & Poors• Stock Guide, earnings are 
estimated even higher in 1963 than they were in 1961 and 
1962. 
UPJOHN COMPANY 
Upjohn is one of the few ethical companies left 
that is still controlled by the founder's family. Among the 
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more important product lines are antibiotics, steriods, nu-
tritional products and since 1957 ORINASE, the first effec-
tive oral treatment for diabetes. 
Upjohn's sales growth has only been 3% to 4% in the 
last three years as compared to an average industry sales 
growth of 10% annually, but what is more important, net in-
come as a percentage of sales was 14.3% as compared to 12.5% 
for the other ethical drug companies. 
The basic reason for the high rate of return is 
the drug ORINASE. The drug costs the company about 0.7 
cents per pill to make and package. It sells, however, to 
the druggists for eight cents! Since the company has a vir~ 
tual monopoly on the market, it can "charge what the market 
bears." 
Let us now consider what conclusions can be drawn 
from the wealth of information presented in the last 20 
pages. 
CONCLUSION 
From the foregoing discussion of the profits in 
the drug industry and the companies that make up almost half 
of the total industry sales, the following conclusions are 
reached by the author. 
PROFITS ARE HIGH 
(1) No doubt about it, profits are high in the 
ethical drug industry. They were already high up to 1954, 
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but from that year on net income as a percentage of sales 
reached a two-digit number for most ethical drug companies. 
Some critics say that the Eisenhower administration can be 
blamed for the increased profits because the administration 
was friendly with business. The author thinks that the 
"wonder drugs" are the basic reason for the high profits. 
As discussed in length in this chapter, there is almost a 
perfect relationship between extremely high profits and 
wonder drug manufacturers. Smith, Kline & French had a prof-
it of 33.1~ on net worth. Carter Products, Inc. had a 38.2% 
return and American Home Products Corporation a 33.5% prof-
it on net worth. The three companies make the leading 
tranquilizers, THORAZINE, MILTOWN, and EQUINIL respectively. 
(2) Profits in the ethical drug industry are 
twice as high as compared to the rest of the industries. 
While the "all industry average 11 is about 6% as a percentage 
of sales, the return for the drug industry has ranged from 
a low of 10.1% in 1952 to a high of 14.6% in 1958 and a 
present level of approximately 12.1%. 
(3) Profitability can also be expressed in the 
following terms. 
(a) Among the 55 most profitable companies 
in the United States, 13 are drug firms! 
(b) Of the 15 companies with the "most well-
kept-up profit margin" in the last four years, 25% are from 
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the drug industry, another indication of the profitability 
of the industry. 
(4) The industry ranks highest if the return is 
measured in terms of invested capital. This standard, as 
already explained, is not the most meaningful but must be 
considered in an evaluation of profits. 
(5) The ethical drug industry has achieved such 
a high profit rate that they were able to finance a large 
expansion program from funds generated from within; and at 
the same time, pay out about 55% of the earnings per share! 
This is quite unusual for a growth industry since companies 
in such an industry must rely to a great extent on outside 
financing. 
OTHER CONSIDERATIONS 
(6) Profits are high no matter how they are meas-
ured but the following factors must also be considered. 
(a) The public demands, and physicians often 
prescribe drugs, especially wonder drugs, unnecessarily. 
The author has often been in a doctor's office when he actu-
ally heard patients ~ the doctor to prescribe certain 
wonder drugs. People like these in the author's opinion have 
no right to complain about high prices because they themselves 
help set these prices through their demands. Phenobarbital 
instead of tranquilizers would do as well in most cases. 
(b) Even those who criticize the drug indus-
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try agree that in relative terms drugs are cheap at any price 
as compared with the cost of hospitalization, prolonged ill-
ness and lives that may be saved with the use of drugs that 
have an undreamed-of potency. 
{c) From the evaluation of profits it has 
been shown that profit margins have;: declined 17% since 1958. 
This is due to: 
(1) The drug investigation by Senator 
Estes Kefauver which resulted in much unfavorable publicity 
and made drug makers more aware of the public. 
(2) Stiffer competition among drug 
makers especially those with wonder drugs. 
(3) Increasing cost of doing business 
because of new government regulations. 
(4) Fear on the part of the drug makers 
that continued unreasonable profits would result in govern-
ment control over drug prices. 
(d) A satisfactory level of profits plays a 
two fold role in connection with research. First, it pro-
vides the reward for successful research and as a result an 
inducement to spend money for this purpose. Without an ade-
quate level of profits the life blood of the industry, new 
drugs, might be shut off. 
(e) Lastly, the ethical drug industry needs 
a higher rate of return because of their greater risk expo-
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sure, rapid product obsolescence, and above average rate of 
growth. However, whether this justifies a rate of return 
twice as high as in other industries will be discussed in 
the next chapter. 
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Profit is merely the index, 
the proof that production was for use. 
No one achieves a profit by producing 
things that are not used. Useless 
things do not bring profitable prices 
and therefore quickly drop out of 
production. 
Gustav Stolper 
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CHAPTER V 
IS THE LEVEL OF INDUSTRY PROFITS JUSTIFIED? 
PROFITS - A REVIEW 
INITIATIVE AND PROFITS 
Profits, as has been indicated in the preceding 
chapter, is the lifeblood of our free enterprise system. 
As David L. Babs~>n put it, "penalize them (profits) and ini-
tiative is throttled, economic growth is retarded and even-
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tually the state takes over." If, however, profits are 
encouraged, the system will flourish. 
Many economists are stressing more and more the 
fact that "there is no more paramount business question to-
day than the outlook and history of profitability of indus-
try.1145 A person not knowing too much about our free enter-
prise system may ask: Why do you put so much emphasis on 
profits? To get a better understanding of profits, the au-
thor will try to determine the functions of profits. 
THE FUNCTIONS OF PROFITS 
According to a policy statement by the U. s. Cham-
ber of Commerce, the functions of profit are as follows: 
(1) 11 A method of sparking and energizing 
human enterprise. 
{2) Stimulate risky, uncertain and innova-
tive undertakings. 
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(3) Allocating human and other resources to 
the most useful purpose. 
(4) Cutting costs and making resources go as 
far as possible.u46 
As the history of the United States has shown, a profit ori-
ented economy is a productive economy. In order to maximize 
profits, efficiency is promoted under such a system. With 
greater efficiency, costs will be cut which may then lead to 
a r~duction in prices. With a reduction in prices, the con-
sumers' purchasing power is increased because his dollars 
. 
stretch further. 
Another important function of profits is to encour-
age risk taking. Without adequate profits, the ethical drug 
industry would not have been able to spend countless millions 
(Lederle has already spent $7.5 million for cancer research 
since 1948 yet sales of cancer drugs amounted only to 
$150,000 in 1959) for research which may never pay off. 
Lastly, without the incentive of profits, what 
would there be left? 
A question often asked is how high should profits 
be? Let us try to find out. 
HOW MUCH IS ENOUGH? 
This question was answered by a group of econo-
mists from the University of Chicago in the following way: 
"Profits should be sufficient to initiate, maintain, and ex-
pand production or the things we want and will buy."47 No-
body agrees as to the exact amount because it varies from 
company to company, from industry to industry and even from 
city to city. It should, however, balance reward against 
risk and stimulate the production of those drugs which soci-
ety requests. The risk, as we shall see in the pages to 
come, is indeed high in this industry. Secondly, since this 
is an industry which can only grow if there is continuous 
research, profits must be high enough to finance such costly 
outlays. 
What, then, is the correct amount of profits? 
According to economists at du Pont "it is not a rigid sum or 
ratio but an amount varying with time and human need. Flex-
48 ibility is its paramount virtue." 
Flexibility is demonstrated in the following chart 
showing the rate of return for the ethical drug industry. 
As Chart IX shows, profits are quite flexible but more im-
portant, the rate of return is not quite as high as is often 
charged. The F. T. C. - S. E. C. {Federal Trade Commission -
Security and Exchange Commission) statistics show that net 
profit after taxes actually decreased from 10.3~ in 1959, 
to 9.2% in 1960, and 9.4~ in 1961. The annual rate of prof-
it on stockholders' equity decreased from 17.8% in 1959, to 
16.8% and 16.2% in 1960 and 1961, respectively. 
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CHART IX 
RATE OF RETURN ON STOCKHOLDERS' EQUITY 
AND NET PROFITS AFTER TAXES 1956-1961 
ETHICAL DRUG INDUSTRY (ALL COMPANIES) 
------------
1'/Sb /1S7 /'ISS' I?S? 11~1 
Source: 
Issues used: Fourth Quarter 1956 
First Quarter 1958 
First Quarter 1959 
First Quarter 1960 
All issues in 1961 
Since there is a certain relationship between high 
prices and high profits, the author will examine drug prices 
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in the following section. 
DRUG PRICES 
As we have seen in Chapter III, Chart II, the cost 
of medical care has increased from approximately $7.5 bil-
lion in 1948 to $21.6 billion in 1961. Expressed in another 
way, medical care as a percentage of personal disposable in-
come went up from 4.5% in 1948 to 5.8% in 1961. How about 
drug prices as a percentage of personal disposable income? 
The following chart shows a very interesting picture. 
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CHART X 
PERSONAL CONSUMPTION EXPENDITURES 
FOR MEDICAL CARE AND DRUGS 
% OF TOTAL DISPOSABLE PERSONAL INCOME 
EXPfNDiTVRr FCR DRVr~5 
J, 
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Source: u. S. Department of Commerce, Survey 
of Current Business, Office of Business 
Economics, (Vol.XLII; No. 12, January, 
1961) , p • 17 • 
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Chart X tells us that there has been a steady rise of medi-
cal care expenditures, between 1949 and 1961, whereas, ex-
penditures for drugs as a per cent of personal disposable 
income has increased only .2% in the same time. In other 
words, while expenditures for medical care as a per cent of 
personal disposable income increased over 30% in twelve 
years, drugs increased by 2~. 
The author feels that a greater understanding of 
drug prices will be gained if average family expenditures 
for drugs and medicines were examined. The Wharton School 
of Finance and the Health Information Foundation made com-
prehensive studies of drug expenditures per family. Follow-
ing are their findings. 
AVERAGE FAMILY EXPENDITURES FOR DRUGS AND MEDICINES 
In the following table we find a breakdown of aver-
age family expenditures for drugs and medicines. The study 
was made in 1950 and covered over 15,000 households. 
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TABLE V 
AVERAGE FAMILY EXPENDITURES 
FOR DRUGS AND MEDICINES 1950 
CITIES IN CITIES IN CITIES IN 
FAMILY INCOME THE NORTH THE SOUTH THE WEST 
UNDER - $ 1,000 $12.29 $12.82 $21.70 $ 1,000 - 2,000 19.31 13.24 21.20 
2,000 
-
3,000 24.98 20.69 24.82 
3,000 - 4,000 27.44 33.56 33.22 
4,000 
-
5,000 26.39 39.95 34.86 
5,000 - 6,000 31.78 50.17 30.11 
6,000 
- 7,500 43.06 36.53 44.63 
7,500 - 10,000 43.72 35.44 64.03 
10,000 and OVER 52.16 64.46 39.33 
Source: Wharton School of Finance, "Detailed Family Ex-
penditures for Medical Care," Study of Consumer 
E enditures Incomes and Savings, Urban U.S.A., 
1 0, Vol. XVI; Wharton School of Finance and 
Commerce University of Pennsylvania, 1957), p. 45. 
In evaluating expenditures by income distribution, the more 
a family earns the higher the expenditures for drugs, but 
this is not true if expenditures are expressed in terms of 
percentage of income. For example, for the $5,000 to $6,000 
income group .55% of personal disposable tncome was spent 
for drugs as compared to 2.4~ for those making under $1,000. 
The $2,000 to $3,000 income group spent 1% of its income on 
drugs. 
In a nationwide study by the Health Information 
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Foundation similar findings appeared. 
TABLE VI 
MEAN GROSS EXPENDITURES FOR HEALTH PER FAMILY 
TYPE OF SERVICE 1952 - 1953 1957 - 1958 % CHANGE 
ALL SERVICES $207 $294 42 
PHYSICIANS 78 98 26 
MEDICINES 31 60 94 
Source: Odin W. Anderson, Patricia Collette, Jacob J. 
Feldman, Famil enditure·Patterns for 
Periodic Health ervices, National Survey -
1953 & 1958, Health Information Foundation), 
p. 7. 
While expenditures for drugs are still lower than those for 
physicians and for dentists, the alarming part is that ex-
penditures for drugs, according to this study, increased 
twice as fast as for other services. However, as was point-
ed out in Chapter I, between 1952 and 1958 great advances 
were made with new medicines. While the average family may 
have spent more for drugs, let us look at what some drugs 
have done for certain families. 
The CORTISONE drugs have restored at least one mil-
lion patients to near normalcy who might otherwise be inva-
lids today. Assume that the average hospital cost per pa-
tient is $1,000 annually; multiplying $1 million patients 
restored times $1,000 amounts to $1 billion saved in hospi-
tal costs. In addition, there was at least as much added 
to the G. N. P. (Gross National Product) because the re-
stored were able to earn money. 
Had all this been made clearer to the public dur-
ing the drug investigations, the public may have appreciated 
the contribution of drug industry a little more. 
Another way of examining drug prices is by analyz-
ing the average price per prescription. Let us evaluate 
them now. 
COST PER PRESCRIPTION 
In 1960 "the number of prescriptions per family 
amounted to 13.5."49 This compares to "eight prescriptions 
in 1954 and eleven in 1959."50 This large increase is due 
to new drugs and greater demand on part of Americans for 
better services. Dividing the average annual expenditures 
for drugs by the number of prescriptions per year, we can 
see an increase in prescription cost from $3.87 in 1954 to 
$5.54 per prescription in 1959. As we have seen in the pre-
ceding chapter, profits of the drug industry increased to a 
two digit number in the mid 50's. Therefore, we can say that 
the increased price per prescription is due to: 
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(1) Increased manufacturers' prices of drugs. 
(2) Introduction of new and very expensive 
· wonder drugs • 
(3) Higher markup on part of druggists. 
The manufacturer and retailer have made sure that they have 
an adequate margin, but what about the wholesaler? How did 
his prices hold up? 
WHOLESALE PRICE INDEX FOR PHARMACEUTICALS 
The following illustration compares the consumer 
price index, medical care price index, and wholesale price 
index. 
CHART XI 
MEDICAL CARE EXPENDITURE INDEX VS. 
WHOLESALE DRUG AND CONSUMER PRICE INDEX 1960-1962 
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Source: U. S. Department of Commerce, Survey of 
Current Business, Office of Business 
Economics, (Vol. XLII; No. 12, December, 
1962), p. s- 7-8. 
The drug industry often uses the following statis-
tics to show how cheap drugs are today: In the last ten 
years the wholesale price index rose only 3% whereas the 
wholesale prices for industrial products rose 22%. This is 
true, in fact wholesale drug prices are still dropping. The 
index for 1962 was 96.1 as compared to 100.2 in 1960. Com-
pare this with an increase in the index for medical care 
from 108.1 in 1960, to 114.1 in 1962. The consumer price 
index, on the other hand, increased from 103.1 to 105.5 in 
the same time. What does it all add up to? Not much! It· 
seems that whenever the wholesaler reduces his price, there 
does not seem to be a drop in the retail price. The retail-
er, in most cases, simply increases his profits by not pass-
ing on the savings to the consumer. This is one reason why 
most experts of the industry think that there would actually 
be no savings to the consumer if doctors would start writing 
for drugs by generic names instead of brand names. 
If anybody should not be blamed for high drug 
prices it is the wholesaler. But the low profit margins are 
hurting wholesalers. Several wholesalers in the New York 
area had to give up their drug department because the depart-
ment was losing money. 
In summary, then, what has the section on drug 
prices shown? 
While average personal expenditures for health 
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"rose from $81 in 1956 to $116 in 1961,"51 wholesale drug 
prices have actually declined over 10% in the same period. 
However, the lower prices were not passed on to the consumer 
since retail drug prices increased over 11% since 1955. As 
we shall see later the druggist accounts for a large part of 
the drug dollar pie. 
The author feels that the retail price index as re-
ported by the Bureau of Labor Statistics is completely inad-
equate. Only the following items are included: "Aspirins, 
milk of magnesia, multiple vitamins; non-narcotic and narcot-
ic prescriptions and penicillin."52 The drugs that really 
hurt the pocketbook are not even included. They include all 
the expensive wonder drugs. According to the Citizens' Com-
mittee for Children of New York City, "antibiotics account 
for 40¢ of every dollar spent on drugs."53 Since this is 
only one of the wonder drugs, the author thinks that the 
items presently covered by the B. L.S. (Bureau of Labor Sta-
tistics) make up only about 40% of the expenditures for 
drugs. Therefore the price index is quite understated. 
Who makes the big profits on drugs? By breaking 
down the drug dollar, we might be able to get a better idea. 
BREAKDOWN OF THE DRUG DOLLAR 
It is very hard to get drug companies to release 
detailed figures on cost of drugs, but the following table 
will give the reader at least some idea of the breakdown of 
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the drug dollar. 
TABLE VII 
COST OF PREDNISONE 5 MG TABLETS PACKED 
IN BOTTLES OF 100 
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TABLET PROCESS CENTS PER TABLET % OF DRUG DOLLARX 
Raw Material 1.18 
Making into tablets .125 
Wastage 3% .036 
Bottling and Labeling .02 
Total factory cost 1.36 cents 4.85 
Research 8.5% of sales 1.52 5.42 
Selling 33% of sales 5.97 21.32 
Overhead, Taxes and Profit 9.05 32.32 
Price to Druggist 17.90 
Druggists' markup about 10.10 36.09 
Retail Price 28.00 cent per 100.00 
pill 
Source: David Cushman Cofle, How to Get Safe Dr~s and 
Cut Their Cost, tWashington, D.C.: Publ~ Affairs 
Institute), p. 10. 
X: Per cent of drug dollar computed by the author. 
In Chapter II when the author discussed supply and demand as 
applied to the drug industry, the point was made that cost 
of production plays an unimportant role in the determination 
of the ultimate price. As Table VII shows, factory charges 
amounted only to 4.8% of the retail price for this particular 
tablet. Research cost, on the other hand, made up 5.4% and 
selling and promotion costs amounted to 21%. The druggist, 
however, takes the biggest piece of the pie: ~. There 
are many companies that offer or suggest an even higher mark-
up. 
To verify the figures of the Public Affairs Insti-
tute, let us now look at the breakdown presented by Life 
Magazine in an article on the ethical drug industry. 
TABLE VIII 
BREAKOOWN OF THE AVERAGE DRUG OOLLAR 
THE DRUG PROCESS % OF DRUG DOLLAR USED 
Research 5% 
Raw Material 4 
Manuracturing 3 Quality Testing 4 
Distribution 2 
Administration 5 
Markup: Wholesaler 15 
Druggist 33 
71% 
Source: "Big Pill Bill To Swallow," Life Magazine, (Vol. 
XLIIX; No. 6, February 15, 1960), p. 97. 
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The difference between 71% and 100% apparently consists of 
selling and promotional expenses, taxes, overhead, and the 
profit margin. As can be seen from an examination of Table 
VII and VIII, the figures coincide quite well. 
In summing up, it is not the manufacturer who 
makes the biggest profit, but rather the druggist who has 
an average markup of 35% to 50% of the retail price. Since 
the druggist will be discussed in another chapter, for the 
time being it can be said that the druggist is a major con-
tributor to high drug prices. 
Manufacturers in their defense for above average 
profits have claimed that the average life span of drugs is 
very short. Let us look at a typical "life chart." 
LIFE SPAN OF THE AVERAGE DRUG 
Due to intense competition and research, drugs 
that were so-called "drugs of choice" {the drug to use for 
a particular illness or disease) yesterday may be outdated 
tomorrow because of the new drugs that come on the market 
almost every second week. Therefore, the life span of the 
average drug is relatively short. 
THE TYPICAL CHART 
On the following page we will find a profitability 
curve and the life span cycle of the average drug. 
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CHART XII 
PROFITABILITY AND LIFE SPAN OF THE AVERAGE DRUG 
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Let us trace the life of the average drug. In the 
first place it probably took several years to develop and 
test it. When it is ready to be marketed often $1 million 
or more will have to be spenti on selling and promotional ex-
penses to introduce the product to the medical profession. 
Since many doctors are conservative, they would not "write" 
for the drug immediately. It will take several detail calls 
and many samples (many of them will never get to the patient 
because I have known many doctors who throw all samples 
away) before the average doctor will start writing for the 
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drug. By that time a year or two may have already passed. 
Now the drug should reach its maximum potential. During the 
entire time the price of the new drug was high because com-
panies must recuperate the high development expenses as fast 
as possible. But this will not last forever because compet-
itors, in most cases, will be ready to introduce a similar 
but often improved product. When competition begins, prices 
will go down and some of the business will be lost to com-
petitors. In due time other companies will come out with a 
vastly improved product and the drug, once a leader, will 
probably settle down to a small share of the market because 
of the introduction of competitive products. 
WHAT IT MEANS 
As we were able to see, the discovery of a spec-
tacular drug will not necessarily mean permanently high re-
turns for the manufacturer. When competition enters the 
market with an improved drug, prices will have to be reduced 
which may affect profits. Ultimately, the company will not 
only have to settle for a normal profit on the drug but may 
even begin to lose money because of the small number of doc-
tors writing for the drug. In many cases the manufacturer 
is reluctant to withdraw the product because it might hurt 
the 11goodwill 11 of the producer. 
The cycle just explained has been the history of 
many drugs introduced in recent years. 
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CAPITAL REQUIREMENTS 
A MAJOR NATIONAL PROBLEM 
The First National City Bank in its "Monthly 
Letter" made the following statement: "The need for more 
capital to provide jobs and finance economic growth is be-
coming re~ognized as a major national problem."54 (Under-
scoring added) This major problem is mainly due to the prof-
fit squeeze; "a continuing squeeze between depressed prices 
and increasing costs."55 
Most industries, but especially the ethical drug 
industry, rely on retention of profits to finance expansion 
since it is the most natural and probably the cheapest way. 
The profit squeeze, however, either does not leave enough 
extra funds to set aside for expansion or there is a lack 
of incentive on the part of companies. The author feels 
that the profit squeeze rather than the lack of incentive is 
becoming a problem in the drug industry. 
In the following chart the capital expenditures for 
the leading ethical drug companies are shown. 
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CHART XIII 
CAPITAL EXPENDITURES-ETHICAL DRUG INDUSTRY 
1952 - 1961 
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Source: Figures computed by the author based upon: 
Standard & Poors, "Capital Expenditures," 
D~s, Cosmetics, (December 13, 1962), 
p. -18. 
As can be seen from Chart XIII, capital expenditures de-
creased from the all-time high of $106 million in 1958, to 
$84 million in 1961, a 20% decline. What happened to prof-
its during this period? Chart IV in Chapter IV tells us the 
story. In 1958 net income as percentage of sales reached an 
all time high of 14.6%. It was in 1958 when the largest cap-
ital expenditures ever were made. However, since 1959 prof-
its as well as capital expenditures have gone down every 
year. Therefore, one can safely make the statement that the 
profit squeeze has hurt ethical drug companies' ability to 
retain an adequate sum for capital expenditures. 
Critics of the drug industry say that the industry 
should use more "outside" funds rather than those generated 
from within. It is true that the industry incurred only $40 
million in funded debt during a period when $670.5 million 
was spent for capital expenditures alone, but it really is 
nobody's business to tell an industry or individual companies 
how to finance their expansion. On the other hand, the au-
thor sees no reason why the drug companies should not employ 
outside sources if they need more funds for capital expend-
itures rather than increase drug prices. 
The drug industry needs larger amounts of capital 
than many other industries because "$1 of invested capital 
in the industry generates only $1.41 in sales as compared to 
such industries as grocery with a sales generation of $9.85, 
meat packing $7.53, and aircraft $5.72. 11 56 In fact the eth-
ical drug industry is in 22nd place of all industries in 
"sales generated by $1.00 of invested capital." Because of 
the small amount of sales generated by $1.00 of invested 
capital, the ethical drug industry contents that this is the 
reason why they need a higher profit margin to provide the 
needed capital. 
In summarizing the findings of this section it 
must be said that the industry needs more capital than the 
average because it is a growth industry, and secondly $1.00 
of invested capital does not generate much in terms of sales. 
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While the above average profits of the industry have financed 
expansion in the past, this will become more difficult in 
the future because of the profit squeeze. 
RESEARCH EXPENDITURES 
RELATIONSHIP OF RESEARCH AND GROWTH OF THE DRUG INDUSTRY 
11 Since 1949 drug industry research and development 
expenditures for ethical pharmaceuticals have climbed 630%, 
while sales have tripled."57 It is often said that "the 
main problem (underscoring added) for the industry (drug) is 
the high cost of research." 58 
These two statements shed much light on the indus-
try's problems. There is no doubt that the industry's growth 
has been phenomenal in the last decade, but this has been 
due almost completely to the enormous research outlays during 
this period which of course have produced the new drugs that 
have made this a major growth industry. This stress on re-
search has resulted in one of the highest proportion of sales 
devoted to research for any American industry. A continuing 
growth of the industry depends directly on the development 
of~ products. This search for new products is the hot-
test part of drug industry competition. For whoever devel-
ops a new product first will get very high rewards. However, 
with the introduction of new products there will be other 
products that become obsolete. 
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OBSOLESCENCE OF DRUGS 
The late Prof. Joseph A. Schumpeter has called the 
creation of new services and remedies "creative destruction."59 
Basically, it means that new products and new techniques 
take the place of the old products. Critics of the drug in-
dustry often say that obsolescence of drugs is due to new 
styles rather than to real medical progress. The author ad-
mits that there is a lot of truth to this statement, but 
there is nothing wrong with improving a present product. 
This can be done in the following ways: 
(1) Improving a present product by trying to 
eliminate side effects. This in itself is highly important 
because many deaths have been attributed to side effects. 
When penicillin was introduced many people died because of 
the side effects. 
(2) New dosage forms are introduced. For 
example, instead of using a drug three to four times a day, 
a "long acting" drug may be introduced which will make it 
easier for patients to take the drug. 
(3) To eliminate the monopolistic position 
of a company, other companies often come out with a similar 
product. This is quite healthy because it creates competi-
tion. 
Rapid obsolescence, however, adds greatly to the 
industry's search for new or improved products. To show the 
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reader how fast the obsolescence is, "nearly 7Cf% of ethical 
sales in 1960 come from products introduced in 1951 or 
later; 20% of 1960 sales come from products launched after 
1957."60 With the high turnover of drugs it becomes ex-
tremely important to make the right decision with regard to 
the particular drug group on which to concentrate research. 
For example, in 1949 nobody had heard of tranquilizers. Yet 
in 1960 this group made up over 8% of the total manufac-
turers 1 sales. On the other hand, vitamins decreased from 
13% of the total sales in 1949 to 4% in 1960. If a company 
is not in the "right boat," its growth may be adversely af-
fected. Therefore it becomes important to search continuously 
for new products. 
THE COSTLY SEARCH 
When the industry spent $197 million in 1959 for 
research, this was called the "biggest privately financed 
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assault on ill health in history." Indeed it was, and it 
has gone up ever since due to the stiffer competition in the 
industry. 
Let us briefly examine the research expenditures 
of the ten leading companies before an evaluation is made of 
these expenditures. 
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TABLE IX 
RESEARCH EXPENDITURES 
FOR THE TEN LEADING ETHICAL COMPANIES 
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----1957----- ----1960----- ----1961-----
ETHICAL EXPENDED % OF EXPENDED % OF ~XPENDED % OF (MIL.$) SALES (MIL.$) SALES (MIL.$) SALES 
Abbott 6.9 5.6 8.2 6.5 9.6 7.4 
Baxter 1.5 5.1 2.0 5.9 2.2 5.9 
Lilly 18.3 9.8 19.7 11.0 20.2 10.2 
Merck 18.6 8.6 21.0 9.6 21.3 9.3 
Parke-Davis 9.5 4.9 12.7 6.3 13.0 7.0 
Pfizer 13.7 5.4 13.4 5.0 13.6 4.3 
Schering 8.0 10.0 8.4 10.1 8.0 9.6 
Searle 3.5 10.1 4.3 11.7 4.4 9.8 
& French 12.1 9.0 13.7 9.4 14.3 8.9 Smith, Kline 
Up john 15.2 9.7 16.0 10.1 18.0 10.8 
Total Expenditures :pl07.3 7-'d'% $119.4 9.6~ $124.6: 'd.3% 
Source: Standard & Poors, "Estimated Research Expend-
itures," Drugs, Cosmetics, (December 13, 1962), 
p. D-10. 
While the research expenditures as a percentage of sales for 
these companies amounted to 8.6% of sales, the industry av-
erage is about 7.5%. For all industries the average is es-
timated at only 3%. The basic reason why the growth of the 
drug industry was achieved is due to the continuing search 
for new products. This search, on the other hand, has taken 
place because the industry could afford it financially. Why 
could the industry afford it? While many other industries 
could just afford to do the necessary research for survival, 
the drug industry went beyond this step and searched for 
the unknown: drugs of unheard of potency. The result: 
phenomenal growth and above average profit margins. Does 
the industry have a right for above average return? This 
can neither be answered in the positive nor in the negative 
way, but it should be said that without the above average 
returns the industry would not have been able or willing to 
spend the sums which are shown in the following chart on the 
next page. 
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CHART XIV 
ETHICAL DRUG INDUSTRY SPENDING ON RESEARCH 
1950 - 1962 (ALL COMPANIES) 
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Sources: Lawrence Lessing~ "Laws Alone Can't 
Make Drugs Safe,' Fortune (Vol. 
LXVII; No. 3, March, 1963~, p. 156. 
Standard & Poors, "Basic Analysis," 
Drugs, Cosmetics, {December 13, 1962), 
p. D-10. 
11Drug Industry Research," The Commercial 
Financial Chronicle, (Vol. CXCIII; 
February 9, 1961), p. 13. 
Oil, Paint & Drug Re~orter, The 
Chemical Authority,Vo1. CLXXVIII; 
No. 5, August 1, 1960). 
Sutro Bros. & Company, "The Drug 
Industry," Monthly Investment Letter, 
(February, 1961), p. 2; 
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Between 1950 and 1962 $1,679,000,000 were spent on research! 
As can easily be seen from Chart XIV, research and develop-
ment expenditures multiplied eight times since 1950, from 
$39 million in 1950, to $248 million in 1962. As Dr. Alan 
Waterman, Director of the National Science Foundation, said: 
"The industries that spend the highest percentage of their 
sales on research and development are almost always those 
with the highest rate of growth."62 The ethical drug indus-
try has accomplished this growth. 
The ploughing back of about $1.7 billion into re-
search represents, as said before, approximately 7.5% of 
sales. (~he figure is an approximation since only total in-
dustry sales are reported. Generally speaking , however, 
about 7Q% of total sales are for ethical drugs. To give the 
reader the clearest picture possible, the research expend-
itures of the ten leading ethical companies which sell pri-
marily ethicals were shown in Table IX) This figure is only 
topped by the aircraft industry, but almost all of that in-
dustry's research is financed by government subsidies. As 
far as government financing in the ethical drug industry is 
concerned, only about 1% comes from the taxpayer; the stock-
holders finance the other 99%. 
The ethical drug industry is often charged with 
being only interested in research that would lead directly 
to patents or other exclusive patent making devices. This, 
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basically, is true because these companies are in business, 
as was noted in Chapter I, to make money. But of the $197 
million spent in 1959 on research, $18 million went to med-
ical schools, hospitals, and other research institutions in 
forms of grants and contracts. In 1962, this figure had in-
creased to "$25 million."63 
CAPITAL AND RESEARCH COSTS COMBINED 
Chart XIII and XIV have shown the extremely high 
capital and research expenditures for the ethical drug indus-
try. The following table combines research and drug expend-
itures as a per cent of sales for a number of industries. 
TABLE X 
COMBINED RESEARCH AND CAPITAL EXPENDITURE 
VARIOUS INDUSTRIES (1960) 
EXPENDITURES FOR 
PROPERTY, PLANT, EQUIPMENT, 
INDUSTRY RESEARCH AND DEVELOPMENT 
AS A PER CENT OF SALES 
Prescription Drugs 13.5% 
Stone, Glass & Clay Products 12.7 
Instruments 9.5 
Chemicals & Allied Products 8.5 
Electrical Equipment 6.2 
Rubber Products 4.2 
Food & Kindred Products 2.2 
Source: National Science Foundation, Funds for Perform-
ance of Research and Development in American 
Industry, 1960, (NSF 61-51(30); 3, U.S. Govern-
ment Printing Office, September, 1961). 
Federal Trade Commission-Securities and Exchange 
Commission, Quarterly Financial Report For Manu-
facturing Corporations, {Fourth Quarter, 1960, 
u.S. Government Printing Office). 
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It comes as no surprise to see ethical drugs as the industry 
with the highest per cent of research and capital expendi-
tures as a per cent of sales. With these necessary expendi-
tures defenders of this industry feel that their profits are 
not "excessive and unreasonable." Indeed it is rather hard 
to imagine how the drug industry could continue to discover 
new drugs at the rate they have been doing it without above-
average profits. 
SUMMARY OF ROLE AND COST OF RESEARCH 
In summing up the role and cost of research, it 
should be pointed out that a satisfactory level of profits 
plays a two-fold role in connection with research. 
(1) It provides the reward for successful 
research and secondly it gives the companies the inducement 
to spend even more in the future. It has been forecast that 
research expenditures will run between $400 to $500 million 
a year by 1970. 
(2) Another contribution research has made 
is that it greatly increased competition in the industry. 
This, the author feels, is a very healthy situation for the 
general public. 
(3) The ethical drug industry has performed 
a service to the nation as well as the entire world by dis-
covering drugs such as antibiotics and tranquilizers which 
have reduced the suffering of many sick people. 
Companies take great risks when they do research. 
Let us look at these high risks now. 
HIGH RISKS 
GREAT PROFITS, GREAT RISKS 
An old Chinese proverb says: "Great profits, great 
risks." 
There is always a degree of uncertainty in the 
ethical drug industry which, it has been said, is perhaps 
the most important single factor accounting for the tradi-
tionally higher earnings. The unstableness is due to many 
reasons: 
(1) Obsolescence of drugs because of the in-
troduction of new drugs. A company never knows whether it is 
going to recuperate the heavy research expenditures, let 
alone make a profit on the drug. Therefore, they must charge 
a high price for a new drug in order to decrease the great 
risk exposure. 
{2) There is often a long lag between the 
investment of funds in a new research project and between 
the date returns can be realized. Since the time lag is so 
great, competing companies may have come out in the meantime 
with a product that is superior, thus decreasing the chances 
of the other company to recuperate its investments and gain 
a share of the potential market. 
{3) Research often does not pay off. Some 
companies such as Lederle have put more than $8 million into 
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cancer research. Although there is a tremendous sales poten-
tial in this market, no effective drug has been found so far. 
As has been pointed out before, the failure ratio in 1958 
was 2,865 compounds to 1. That means out of 2,865 compounds 
synthesized, only~ compound ended up as marketable drugs! 
(4) Some drugs look successful in clinical 
tests, but they disappoint in actual practice. This could 
be due to undesirable side effects and doctors' and patients' 
perfe~ences change. As to undesirable side effects, one re-
cent example can be cit~d. The thalidomide affair is prob-
ably still remembered by everyone. The drug had been used 
in Europe by millions as a sleeping pill since 1956. Then 
a United States company, the WilliamS. Merrell Company, ac-
quired the right to market the drug here . All of a sudden 
there were reports of malformation in babies. After the 
company had spent untold sums of money on clinical tests, 
the drug naturally had to be dropped. Result: much money 
was lost. 
During the first half of 1962, only 16 new drugs 
were introduced. As we can see from Chart XIV, $248 million 
was spent for research in 1962. A tremendous sum! The intro-
duction of new drugs is down 3~ from 196l .. There was not 
only a lack in breakthrough of drugs, but an increasing cau-
tion on part of manufacturers because of the large number of 
drugs that had to be recalled from the market during the year 
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Why do companies take risks? Because they may get 
a reward for taking the risk. 
REWARD FOR SUCCESS 
When a company has finally been able to introduce 
a drug, its price is likely to be quite high. This, in the 
author's opinion, is the only way the investment can be re-
cuperated. In addition, there were aany failures mentioned 
in the preceding section. In order to have enough money 
available for continued research, a high price must be charged. 
The price goes down, however, as the years pass. 
In sunnnary, then, the Chinese proverb: "High Prof-
its, high risks" has a real meaning in the ethical drug in-
dustry. The only way to take on high risks is to have high 
profits. 
Critics have often charged that it is the monopoly 
in the industry that caused high profits. Is there a mono-
poly? 
MONOPOLY IN THE DRUG INDUSTRY 
FAILURE RATE 
As has been said in Chapter I, there are 1,300 
companies in the drug industry of which only 28 exceed sales 
of $8 million a year. These 28 companies account for 90% of 
all drug sales. 
Before we analyze this concentration let us look 
at the failure rate in the industry. 
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TABLE XI 
FAILURE RATES IN THE U.S.A. (SELECTED INDUSTRIES) 
INDUSTRY FAILJRES 
1955 195~ 19~9 1960 
Total 10,969 14,964 14,053 5,445 
2,465 Mining & Manufacturing 2,202 2,680 2,612 
Textile, Mill Products & Apparel 506 493 420 
Chemicals & Allied Products 49 66 62 
Source: Statistical Abstract of the U. s. A., Indus-
trial and Commercial Failures, (82nd Annual 
Edition, No. 665, Government Printing Office, 
1961), p . 498. 
Admittedly, the failure rate shown in Table XI is for the 
entire chemical industry, but even so the failure rate was 
only 3.5% of ~11 failures in 1955, and 4.1% in 1960. Since 
the breakdown for the ethical drug industry is not given, no 
correct figures can be cited. The author, however, knows of 
no ethical drug house that has gone out of business in the 
last few years. Thus failures are not common in the ethical 
drug industry. 
COMPETITION 
A CHANGING PICTURE 
In the following table the concentration of sever-
al industries can be observed. 
435 
63 
87 
TABLE XII 
PER CENT OF TOTAL SHIPMENTS 
MADE BY LARGE MANUFACTURING COMPANIES 
(SELECTED INDUSTRIES) 1947 & 1954 
PER CENT OF TOTAL VALUE OF 
SHIPMENT ACCOUNTED FOR BY 
CENSUS NUMBER OF 4 LARGEST 8 LARGEST 20 LARGEST 
INDUSTRY YEAR COMPANIES COMPANIES COMPANIES COMPANIES 
Pharmaceutical 
Preparations 1947 1123 28 44 64 
1954 1128 25 44 68 
Cigarettes 1947 19 go 99 100 
Motors & 
G~nerators 1947 224 59 66 80 
1954 266 50 59 75 
Source: Statistical Abstract of the U.S.A., "Large 
Manufacturing Companies, Per cent of Total 
Shipments Made By Large Manufacturing Compa-
nies in Selected Industries," Statistical Ab-
stract of the U.S.A. (No. 1094, 1961), p. 793. 
In the cigarette industry we have the big five, in the auto-
mobile and in business machine industries the big three, and 
in the meat packing and aluminum industries the big four. 
The drug industry, as noted, has 28 companies which account 
for 90% of total sales. From Table XII it can been seen that 
the four largest companies accounted for 28% of total sales 
in 1947 and 25% in 1954. Not one single company accounts for 
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more than 10% of total industry sales. While eight compa-
nies in the cigarette industry accounted for 99% of indus-
try sales in 1947, the eight leading drug companies ac-
counted for 44% of total sales. In a recent study by Arthur 
D. Little, Inc., it was shown that 37% of the industry sales 
were accounted for by five companies. This is a decrease 
from the 49% in 1951. 
These figures really do not give us a clear pic-
ture of the concentration in the industry. The following 
evaluation might be more meaningful. 
MAJOR PRODUCT AREA 
Antibiotics, which make up almost 25% ($830 mil-
lion in 1961) of total manufacturers' sales, are made by 
"28 companies."64 Of these 28 companies, 12 dominate the 
field. In 1950 there was only one company that manufactured 
that drug. The competition that has developed in the field 
is very intense. In fact it finally led to a 15% cut of 
antibiotic prices during the first half of 1962. From his 
experience as a detailman, the author remembers the large 
quantities of samples, large amounts of promotional material, 
and the expensive service pieces that detailmen left with 
doctors so that they would prescribe their product. Compe-
tition? Real, stiff competition indeed! 
The second largest drug group is hormones. Sales 
amount to about $260 annually. However, here we have several 
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subsections such as sex hormones, cortico-steriods, and non-
steriod hormones. There are eight companies which dominate 
the field of sex hormones. Having detailed one of these 
products myself for six months, the author can vouch for the 
competition in this field. There is particularly strong com-
petition from the generic name drugs, which are always 
cheaper than brand names. 
In the corticoids field we have Lederle, Lilly, 
Merck, Schering, Squibb and Upjohn who dominate the field. 
In 1950 Merck was the only company with a steriod. 
By 1954 its share of the market had decreased to 27% becaus~ 
competing companies had entered the field. By 1956 it was 
down to 3%. Things change fast in the ethical drug indus-
try. These changes are due to competition. It was the re-
search and development program which has brought about these 
changes. 
The non-steriod field has three leaders. Here, 
too, we have seen price pressures recently because supply 
exceeds demands. 
Another big field are tranquilizers. About $288 
million were sold in 1961. Carter and American Home Products 
Company have had a large share of this market for years. It 
was in this drug group where some real problems have existed. 
The two leading tranquilizers Miltown and Equinil have not seen 
major price reduction for some time. In fact the Veterans 
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Administration was finally forced to buy tranquilizers 
abroad because Carter , which is the U. S. patent holder, 
would not go below the $19.25 price. In the last few years 
other companies have entered the mild tranquilizer field and 
some competition seems to have developed. 
Vitamins, which once accounted for 14% of total 
manufacturers' sales, now contribute only 4%. In this 
group competition is intense. It is due to "over the 
counter" promotion of vitamins and low cost imports. Only 
recently bulk producers have announced a "15% to 30% de-
crease on prices for bulk vitamins."65 
As we could see from an example in Table I, Chapter 
I, there are many identical bids to government agencies on 
the part of ethical drug producers. Is it due to monopoly? 
At times it might be, but "identical bids may sometimes be 
more honest, more competitive, more practical than any other 
kinds of bids."66 Defenders of identical prices say that 
companies must charge a "going price." Also, when one com-
pany reduces prices others will follow. Then the price will 
stay at that level for some time before another downturn or 
upturn occurs. With more intense competition from abroad, 
prices may go down and we may see fewer identical bids. 
According to Senator Estes Kefauver, the patent 
system is the primary reason for the high drug prices. His 
bill (81552) would have reduced the patent protection from 
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17 to 3 years. (The Senate did not pass this part.) Why is 
our patent system so good or bad? 
THE PATENT LAW 
THE PRIMARY VILLAIN 
During the drug investigations in 1959 and 1960, 
Senator Estes Kefauver said that the patent system was the 
primary villain of high drug prices and high drug profits. 
A brief review of the system is necessary. 
Abraham Lincoln once said that "the patent system 
adds the fuel of interest to the spark of genius."67 We 
have seen that companies are spending millions of dollars 
each year to develop new drugs. Without the protection of 
the patent law there would be no incentive to do research 
because as soon as a company has developed a new drug others 
could simply copy the drug without incurring the research 
costs. 
Of all countries in the western world only Italy 
has no patent protection for new drugs. As a result Italy 
has not produced a major drug. But as we will see later, 
Italy is a master in copying drugs from other countries. If 
every country had such a system, there would have been hardly 
any progress in the development of new drugs. 
In the U. S. A. companies are working very hard to 
discover new drugs and get a patent for it. Of course not 
all can be first. "And there is no such thing as a second-
best drug, any more than there is a second-best poker hand."68 
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Often when the two companies come out with a new drug at ap-
proximately the same time, a long fight will develop over 
who should get the patent~ In the meantime such coat-tail 
riders as PREMO Company can copy the drug and sell it for 
any amount because they do not have to take out a license. 
Once a patent has been granted to a company for a 
new drug what will other companies do? For one thing they 
can ask the company with the patent for a license. 
CROSS LICENSE 
Cross licensing has increased in the last few years 
because of the decrease of the number of new drugs intro-
duced. Cross licensing simply means that the company with 
the patent will allow another firm to sell the same product 
under a different brand name. Carter Products, Inc., which 
was the patent holder for the first tranquilizer, granted a 
license to Wallace Laboratories. Companies usually pay an 
~% royalty for the license. When a cross license has been 
granted competition usually begins for the greatest share of 
the market. Since there is hardly a difference in quality, 
whatever company has the best detail staff and the best pro-
motional staff will get the greatest share of the market. 
From observation of such cross-licensing it seems that there 
is a lack of price competition. Only when another company 
comes out with a similar but chemically different product 
will price competition really start. 
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In order to generate more competition Senate 
Kefauver suggested· a reductianof patent protection from 17 
to 3 years. Is this a proper solution? 
A SOLUTION? 
To take the mystery out of the question, this part 
of 'bill Sl552 was not passed. 
Would a growth industry such as the ethical drug 
industry have been able to continue to grow if the protec-
tion had been reduced from 17 to 3 years? 
In order to risk great sums on research and devel-
opment, a company must be sure that it will recuperate the 
investment. If the patent protection had been reduced to 
three years it is the author's feeling that many companies 
would think twice before investing millions of dollars to 
develop a new drug. On the other hand Senator Kefauver 
would not have reduced the patent protection completely be-
cause he only wanted to force a company to grant licenses to 
other companies at the end of three years for a certain roy-
alty. 
The author thinks that the part of bill Sl552 
dealing with patents would have had a chance of passage if 
the protection would have been reduced to ten years instead 
of three years. As we have seen from Chart XII it takes 
quite a while before a new drug is accepted by the average 
doctor. After the THALIDOMIDE affair doctors have become 
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even more conservative than they were before. Therefore, 
the three year patent protection is inadequate. It would 
not have given companies enough time to recover investment 
costs. Also, many senators were probably quite dissatisfied 
with the section in the law that forced companies to grant 
a license. American firms are accustomed to choosing their 
own licensee and to stipulate their own terms. 
What, then, should be done about the present pat-
ent system? In the author's opinion it would probably be in 
the best interest of all concerned to let the drug companies 
have the same protection as is granted to other industries. 
Not a week goes by without a patent litigation in 
the ethical drug industry. Merck and Company, which only 
recently had to guard its patent on Vitamin B12 against 
Squibb, will now have to put up a "vigorous defense of its 
vitamin patent against Richter Pharmaceuticals."09 Even 
with the 17 year protection many small drug houses produce 
patent protected drugs illegally. 
Senator Kefauver and other critics of the drug in-
dustry often say that there is a monopoly in the industry. 
In preceding pages the author has tried to evaluate this 
problem. The following section may help the reader in arriv-
ing at a conclusion concerning this subject. 
COST OF ~ROMOTION 
A NEED FOR INFORMATION 
A new discovery, no matter how great it was, can 
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not alone cure a single living person or disease. No drug 
can accomplish anything until doctors know about it and 
until it is available at the local drugstore. 
With the discovery of the drug the tough job is 
not finished. Now equal zeal and energy must be devoted to 
the task of education and distribution. Education can be 
accomplished in three ways. 
(1) Direct mail. Doctors have told the 
author that they are getting over 100 pieces of literature 
each week. The degree of effectiveness is hard to measure, 
but many p~eces never seem to reach the doctor because the 
nurse throws them away when she sorts the mail. Nevertheless, 
25% of the doctors get new product information from direct 
mail literature. 
(2) Publication advertising. In order to 
reach the 250,000 physicians in the United States, many com-
panies (some exclusively)_ rely on medical journal ads. Ac-
cording to a survey by the American Medical Association in 
1959, 32% of the doctors surveyed indicated that they rely 
on journal ads for new product data. 
(3) Detailman. Since we have already dis-
cussed the detailman, it can only be repeated that 68% of 
all doctors interviewed felt that the detailman is their 
best source of new product data. 
In order to make a profit, a company must be able 
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to sell its goods or, as in the case of the ethical drug in-
dustry, to educate the doctors about their products so that 
they can prescribe them. How. high are the promotional costs 
in the ethical drug industry? 
ADVERTISING EXPENDITURES 
A decade ago "75% of the prescriptions were com-
pounded in xhe drugstore itself. Today, more than~ of 
all prescriptions call for already prepared tablets."7° 
How significant is this statement? In the author's opinion 
it is quite significant. It shows how effective drug com-
panies have been in "educating" doctors in prescribing drugs 
in terms of "brand names" instead of generic names. By doing 
so the druggist has no choice but to give the patient the 
specific drug the doctor requested. If the doctor had writ-
ten the generic name of the drug on the prescription, the 
druggist would have had a choice of probably 100 different 
drugs from 100 different drug companies all with the same 
generic name. Then it would be up to the druggist, not the 
doctor, to choose the company with the best quality and as 
far as the druggist is concerned, with the lowest price or 
highest gross margin to him. As can be seen, this would 
have meant a shift of responsibility from the doctor to the 
druggist. 
The shift in recent years to brand name drugs has 
been criticized by opponents of the drug industry. It has 
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been said that this shift was due to "brainwashing o:f doc-
tors."71 Some critics {see Harvard Business Review, September-
October, 1962, p. 97) have gone so far as suggesting that 
vigorous promotion of drugs is not necessarily socially 
desirable. But apparently there has always been a problem 
in drug advertising because as early as 1920 "the advertis-
ing of trade marked products was greater in the drug and 
toiletry field than in any other group."72 
How high are the expenditures for promotional ac-
tivities? Advertising Age estimated that $450-000,000 were 
spent by the major drug and toilet article manufacturers in 
1960. Since this amount will not tell us how much was spent 
by drug companies let us look at the direct mail and medical 
publication expenditures of the companies with the highest 
expenditures. 
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TABLE XIII 
TOP ETHICAL DRUG ADVERTISERS, 
MEDICAL PUBLICATION EXPENDITURES AND 
DIRECT MAIL COST, 1960 
EXPENDITURES 
ETHICAL COMPANY IN DOLLARS 
Wallace Laboratories $6,000,000 
Merck, Sharp & Dohme 5,500,000 
Smith, Kline & French 5,000,000 
Parke-Davis 4,600,000 
Ciba 4,500,000 
Lederle Laboratories 4,000,000 
Chas, Pfizer 4,000,000 
Roche Laboratories 3,700,000 
Source: Advertising Age, (October 16, 1961), p. 111. 
Wallace Laboratories spends the largest amount because this 
company does not employ detailmen. Merck which had sales 
totaling $218 million in 1960, spent $5.5 million dollars on 
direct mail and in medical publications excluding the ex-
penses for detailmen. Smith, Kline & French spent 3.4% of 
total sales on these two media alone. 
REAL COMPETITION 
It has been estimated that in one year about 3.8 
billion pages of paid journal advertising are placed in 
journals. Many people feel that this is quite excessive. 
In fact many opponents of the in:iustry charge that the "only 
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real competition is the tremendous competition for the eye 
and ear of the physicians."73 But isn't it an indicator of 
competition? Why would a company bother spending so much 
money if they were assured a ready market? It is the 
author's opinion that the large promotional expenditures are 
a definite indicator of competition. 
Combining promotional and selling expenses, about 
16 to 25 cents of each sales dollar are spent for these ac-
tivities! Very few industries have a higher ratio . 
WHAT IS THE SOLUTION? 
Many suggestions have been made as to how to re-
duce this high ratio •. Setting up of satisfactory noncommer-
cial sources was one suggestion. The industry already has 
the Physical Desk Reference, a commercial source, which lists 
all brand name drugs in the United States. This reference 
is very popular among physician and a noncommercial source 
would be a duplication of efforts. 
It is also said that if information is readily 
available, physicians will take the initiative to see that 
they keep up to date. From personal experience the author 
knows that many physicians do not even have the time to lis-
ten to detailmen, let alone take their own initiative to 
gather information. 
Those who are in favor of generic drugs say that 
the doctor is not interested in the reputation of a company, 
only in the properties of the drug. Having put this state-
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ment to a number of doctors, the author received a unanimous 
reply that a doctor has neither the time nor facilities to 
inspect the drugs. All said they rely on the company's rep-
utation solely. 
The present promotional system is quite expensive 
for the patient {he pays for the cost when he buys the pill), 
it must be admitted. But it is effective, as has been shown 
in the dramatic change from generic to brand name drugs. 
USE OF PROFITS IN THE ETHICAL DRUG INDUSTRY 
A growth industry such as drugs has to plough a 
lot of money back into the business for growth and progress. 
As we have seen in this chapter, between 1950 and 1962 almost 
$1.7 billion were spent on research alone. Also, a lot of 
money was needed for plant and equipment. 
An examination of financial data of ethical drug 
companies for 1961 show that 50% of the industry profits 
went for income taxes, 30% went to stockholders, and 20% was 
ploughed back for plant and equipment, increase of working 
capital , etc·.. For 1959 the figures were 50%, 29%, and 21%, 
respectively. Since most of the expansion is already fi-
nanced with the stockholder's money, it will probably be dif-
ficult to decrease the dividend payout even more. Otherwise, 
the hundreds of thousands of Americans who have invested 
their savings in drug concerns may think twice before they 
invest more money in this industry. 
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What conclusion can be drawn from the evidence 
presented in this chapter? 
HIGH ~ROFITS JUSTIFICATION-PRELIMINARY CONCLUSION 
It has often been said that there are three factors 
that keep prices high in the drug industry. 
(1) The patent system 
(2) Advertising and promotional expenses 
(3) Monopolistic conditions 
As far as the patent system is concerned, it may be a 
11pr1mary villain" to high drug prices, but we have also 
noted in the preceding sections the relatively short life 
span of the average drug and the large sums companies must 
spend on research to develop the drug in the first place. 
The author feels that drugs should be granted the same 
patent protection as any other American industry. Otherwise, 
there may be a lack of incentive to put millions of dollars 
into new research projects. 
Advertising and promotional expenses have also 
been analyzed. The costs are high, but are paying off for 
drug companies because of the switch from generic name drugs 
to trade names in the last decade. I1' the hard hitting 
direct mail and journal advertising campaigns were reduced 
to some extent, (doctors are already reporting progress in 
this direction because the number of pieces of direct mail 
is down to about 65 a week) it would result in considerable 
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savings which may then be passed on to the consumer. 
Lastly, the question of monopoly has been examined 
and it was found that there has been a certain lag of com-
petition in some drug groups, especially tranquilizers, but 
with the entry of companies with chemically different tran-
quilizers, competition seems to have developed. Also, with 
greater competition from abroad in this specific field, 
prices may be coming down. 
A more thorough conclusion of conditions in the 
industry will follow in a later chapter, together with re-
commendations as to how to eliminate some of the problems. 
103 
CHAPTER VI 
PRICES OF DRUGS VS. PROFITS OF DRUG HOUSES 
HOW ARE PRICES SET IN THE INDUSTRY? 
What shall we charge for product X? This is a 
question which is probably asked thousands of times every 
day by marketing men all over the country. 
As has been shown in Chapter V, the determination 
of a price is not a science. It depends on many variables 
and these variables change from industry to industry. In 
the ethical drug industry the actual cost of manufacturing 
the drug plays no role in the ultimate price. Rather it is 
the demand for the new drugs; the competition that already 
exists in that particular drug group (hormones, for example} 
and the research and development costs of the new drug that 
are considered in determining the ultimate price. 
NEW DRUGS AND HIGH PRICES 
When a new drug is marketed before competing drugs 
can be discovered, the richest earnings occur. Unless there 
are large earnings, "the quick kill with the quick pill does 
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not pay off." For example, Lederle, after many years of 
research had discovered what seemed to be a major break-
through against pneumonia. Sales were excellent until the 
sulfa drugs came along 1~ years gfter the introduction of 
Lederle's drug. Millions of dollars in research costs had to 
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be written off because Lederle's drug was outdated. The 
company probably derived glory for saving many lives but 
nothing else. 
This is typical of what can happen in the pre-
scription industry. It is probably for this ever present 
uncertainty and high risk that a firm sets a relatively high 
price on a new drug. The price, however, of the new drug 
will not remain at this level forever. Depending upon the 
degree of competition, prices may drop fast. For example, 
"potassium and procaine penicillin were quoted by $1,300 per 
billion units in 1948, and as low as $34.50 for potassium in 
1955 and $47.50 for procaine in 1956."75 Production effi-
ciency as well as competition have helped to decrease the 
price. 
No matter how one looks at it, drug prices are 
relatively high; but when they are compared with drug prices 
overseas, then they look completely out of line. The author 
will try to analyze the reasons for the big price differen-
tial in the following section. 
WHAT THE DRUG DOLLAR BUYS 
AS COMPARED TO FOREIGN COUNTRIES 
During the 1959 and 1960 drug investigations by 
Senator Estes Kefauver, it was often pointed out that Ameri-
can firms charged far less for the drugs they sold overseas 
than what they charged in the United States. EQUINIL, for 
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example, sold for half the price in Germany. 
What is the reason for the lower price? Opponents 
of the drug industry claimed that monopoly and promotional 
practices are the reasons for the higher prices in the United 
States. While promotional costs are high in the United 
States, they are equally high in Europe. It is the author's 
opinion that they are even higher overseas because doctors 
act as detailmen in some countries of Europe. As far as 
monopoly is concerned, the author analyzed the various drug 
groups in the preceding chapter and found a lot of competi-
tion in most groups. With monopoly and excessive promotional 
costs discounted, let us look at the real reason for lower 
drug prices overseas. 
WHY DRUG PRICES ARE LOWER OVERSEAS 
Drug prices are lower overseas in terms of dollars, 
but are the Europeans getting paid in dollars? We must look 
at the'purchasing power of the currency overseas. Having 
worked both here and abroad, the author has had the experi-
ence to make a just comparison. While 1200 DEUTSCHE MARK 
(German mark) is a good salary in Germany, hardly anyone can 
live on $300 a month (exchange rate is 4:1) in the United 
States. Therefore, it would be better to look at the "real" 
price of the drug, the hours of work required of the average 
person to buy a pill. To gain a better understanding of the 
subject, let us first look at the hourly earnings in various 
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countries. 
TABLE XIV 
HOURLY EARNINGS IN SIX COUNTRIES 
AVERAGE HOURLY EARNINGS 
COUNTRY ~ALL MANUFACTURING) 
United Kingdom 67.2 cents 
West Germany 53.8 cents 
France 47.3 cents 
Japan 35.9 cents 
Italy 34.9 cents 
U. S. A. $2.41 
Source: U.S. Department of Commerce, Survey of Current 
Business, "Hourly Earnings, All Manufacturing," 
Office of Business Economics, (Vol. XLII; No. 12, 
December, 1962), p. S-15. 
"Hourly Wages in Five Countries," Business In-
ternational, Weekly Report To Management of 
Business Abroad{ (No volume number given; De-
cember 29, 1961), p. 2. 
Table XIV shows that American earn three to four times as 
much in an hour as their counterpart in other leading coun-
tries of the world. Will a West German, who earns 54¢ an 
hour, get a bargain when he pays only half as much for a 
tranquilizer as his American counterpart? In the following 
table the hours of work required to pay for the tranquilizers 
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are shown. 
TABLE XV 
HOURS OF WORK REQUIRED 
TO BUY DRUGS IN THE U.S.A. AND ABROAD 
(1957 RETAIL PRICE OF TRANQUILIZERS) 
HOURS OF WORK 
RETAIL PRICE REQUIRED TO BUY 
COUNTRY IN U.S. DOLLARS 50 TABLETS (25 MG) 
France $ .77 1 HOUR 57 MINUTES 
U. S. A. 5.05 2 HOURS 18 MINUTES 
West Germany 1.90 3 HOURS 18 MINUTES 
Italy 1.62 4 HOURS 46 MINU~ES 
Japan 2.29 7 HOURS 38 MINUTES 
Source: Pharmaceutical Manufacturing As·sociation, The 
Better Life A Chart Stor of Dru s and the--
Drug Industry, No volume number given; 19 1), 
p. 29. 
While a West German worker only pays $1.90 for 50 tranquil-
izers as compared to $5.05 in the United States, the German, 
on the other hand, must work almost 1~ times a~ long as the 
American in order to buy the tranquilizers. The Japanese 
will have to work 3~ times longer than Americans to buy 
tranquilizers which cost the Japanese half the U. S. price. 
In summary Americans are still better off than most 
foreigners even with the high price of drugs in the U. S. A. 
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HIGH DRUG PRICES AND THE PHARMACIST 
In Chapter V, Table VIII, we have seen the large 
markup the pharmacist adds to the wholesale price. There 
are several reasons why the pharmacist's markup is so high. 
HIGH MARKUPS AND THE PHARMACIST 
The pharmacist, unlike most other retail groups, 
is still following the suggestion that the best way to build 
up profits and sales volume is by "maintaining fair pricing 
schedules."76 With the exception of a few large states, 
noticeably New York, pharmacists have been able to control 
the entry of price cutters into the drug trade. In addition, 
the drug chain has not yet become very important in those 
states where "fair trade" is still being practiced. 
Many times the author has come into a doctor's 
office, only to be told that the druggist had charged a lot 
of money for drug X. Closer questioning revealed that the 
druggist actually charged 50% more than he should have charged, 
assuming a normal markup of 45%. Drug makers, when confronted 
with this problem often say: "What he (the druggist) charges 
the customer is entirely his own affair."77 With greater 
control and greater interest over resale prices, the drug in-
dustry would not only help themselves by avoiding the demand 
for cheap generic name drugs, but the public would certainly 
appreciate the lower prices too. 
With the high markup for brand names there is no 
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good reason to believe that the druggist would pass on the 
savings of the cheaper bulk materials to the customer if doc-
tors would start writing drugs by generic names. 
In the table that follows, net profits of the 
average pharmacy are shown, together with sales. 
TABLE XVI 
AVERAGE OF RETAIL PHARMACY OPERATION {1952-1961) 
PROPRIF11.'0R'S OR 
YEAR SALES MANAGER 1 S SALARY NET PROFIT 
1952 $ 95,985 $ 6,734 $5,694 
7,540 1953 
1954 
1955 
1956 
1957 
1958 
1959 
1960 
1961 
Source: 
97,090 5,285 
101,881 8,116 5,193 
102,842 7,790 5,743 
111,445 8,470 6,464 
126,466 9,739 7,029 
126,191 10,151 6,484 
134,238 10,861 7,679 
138,342 11,377 7,301 
139,176 11,595 7,162 
F. C. Hecker, The Lilly Digest 1961, (30th 
Annual Edition, Copyright 1962), p. 48. 
Between 1952 and 1961, the average pharmacist not only in-
creased his net profit from $5,694 to $7,162, but in addi-
tion the proprietor's salary almost doubled during this time. 
The drug trade is quite profitable and failures are quite 
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uncommon. Of the 55,000 drugstores that existed in the 
U. S. A. in 1961, only 11 2041178 went out of business. This, 
by the way, is the smallest number of failures of all re-
tail trades listed in the Statistical Abstract of 1962. 
Another way of measuring the profitability of 
drugstores is by analyzing the price per prescription the 
druggist charges. 
TABLE XVII 
AVERAGE PRICE PER PRESCRIPTION (1950-1959) 
NUMBER OF PRICE PER 
YEAR PRESCRIPTIONS FILLED PRESCRIPTION 
1950 9,020 $ 1.77 
1951 9,875 l.QO 
1952 10,436 2.08 
1953 10,295 2.19 
1954 11,037 2.27 
1955 11,273 2.46 
1956 11,985 2.62 
1957 13,502 2.85 
1958 13,693 2.96 
1959 14,656 3.09 
Source: "Drug and Toiletry Study," This Week Magazine, 
{No volume number given; 8th Biennial, 1960), 
p. 25. 
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It must be admitted that the 50's were the period of the 
wonder drugs, but a price increase of 43% per prescription 
between 1950 and 1959 is quite high if the figure is com-
pared with a wholesale price increase of only 3%. Apparent-
ly the druggist has increased his already high markup even 
more. 
Many drug makers sell one or two "over the counter" 
preparations. If the drug makers did not need the cooperation 
of the druggists for these items, the author is sure that we 
would see a more energetic drive on part of the ethical drug 
industry for more reasonable markups of their drugs. 
THE M.D. AND HIS RELATIONSHIP TO PROFITS 
The author knows many doctors who own stock in the 
ethical drug industry. As far as the drug firms are concern-
ed, they should be quite happy about this relationship (doc-
tors and ethical drug stocks) because the doctors in most 
cases will prescribe the drug of the companies of which they 
are stockholders. It stands to reason that the doctor-stock-
holder is interested in high profits for his firm. How wide-
spread the relationship between doctors and ownership in 
ethical firms is, can not be estimated. However, the more 
widespread this relationship, the harder it will be to talk 
doctors into prescribing in terms of generic name drugs be-
cause this oould mean a decrease in ethical firms' profits. 
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Having now analyzed prices of drugs vs. profits of 
drug houses, let us now look at the contribution the ethical 
drug industry has made to the well-being of mankind. 
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CHAPTER VII 
THE DRUG INDUSTRY AND THE WELL-BEING OF MANKIND. 
WORLD LEADER IN DISCOVERY 
Drug prices and profits may be higher in the United 
States than in any other country of the world, but credit 
must be given to the United States drug industry for the 
discoveries that have been made here. In the following 
table drug discoveries are shown by country of origin. 
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Source: "Piracy - A Rising Worry For U. S. Business," 
U. s. News and World Report, Special Report, 
(Vol. LIIIj No. 10, September 3, 1962), 
p. 83. 
Chart XV was based on 161 major drugs now in wide use. Of 
these the United States discovered almost half while Germany, 
which has always been strong in drug discoveries, was in 
second place. Italy, which has no patent law for drugs, has 
not had a single major drug discovery. 
As we have seen in the preceding chapter, returns 
can be quite high for new drugs. The high returns, combined 
with the patent protection, are probably the basic reasons for 
the high rate of discovery. These new discoveries have not 
only helped people in the United States, but also many suf-
ferers in foreign countries who are thankful to the United 
States for its help. 
To the credit of the industry, drug firms often 
develop products for which there is only a small market. 
Such pharmaceuticals are often calilied custom made prepara-
tions. 
CUSTOM MADE DRUGS 
The drug industry is basically only interested in 
those products that have a potential market. However, at 
times, drugs are introduced whose market potential is very 
small. For example, a product has been introduced for the 
prevention of mental deterioration in children with a certain 
metabolic disease, of which there are less than 1,000 known 
cases. Then there is the drug for a rare type of epilepsy 
of which there are only thirty known cases. 
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With demand so small in many cases, the unit cost 
would be so high that none of the people with the sickness 
could afford the pills. Manufacturers usually set a fair 
price for such a drug and the loss must naturally be absorb-
ed by the few best selling pharmaceuticals. This is another 
reason why it is often hard to look at one fast moving drug 
and compare the selling price with the production costs. 
What one can not find in these figures are research costs of 
the less successful and wholly unsuccessful drugs, and, of 
course, the drugs for which there is no large market. Coat-
tail riders, which were discussed in Chapter II, may be able 
to produce fast moving drugs at a lower cost than the research 
firms, but they are completely disinterested in drugs for 
which there is only a small demand. 
In summing up, there may be high profits for cer-
tain drugs, but o.ne must also consider that there are man}t, 
many other drugs a company carries that are actually loss 
leaders. 
In the preceding 100 pages we have seen that drug 
firms have a higher rate of return than most other industries. 
We have also seen tremendous capital and research expenditures 
on part of drug manufacturers. What have all these expendi-
tures resulted in? In short, they resulted in high profits, 
but also in the greater well-being of mankind. 
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ACCOMPLISHMENTS OF PHARMACEUTICAL RESEARCH 
The drug industry can not claim all the credit for 
the excellent health statistics that follow, but new drugs 
have made a great contribution toward the well-being of man-
kind. 
TABLE XVIII 
DEATH RATE PER 1,000 POPULATION 
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DEATH RATE PER DEATH RATE PER 1,000 DEATH RATE PER 1,000 
YEAR 1,000 AT BIRTH UNDER ONE YEAR 75-84 YEARS 
1910 
1920 
1930 
1940 
1950 
1960 
Source: 
14.7 131.8 122.2 
13.0 92.3 118.9 
11.3 69.0 112.7 
10.8 54.9 112.0 
9.6 33.0 93.3 
9.5 28.8 87.0 
u. s. Department of Commerce "Vital Statis-
tics, Health and Nutrition,~~ Statistical A11-
stract of the U. s. A., (83rd Edition, No. 67, 
No. 49), p. 52 & 63. (1962) 
Death rate per 1,000 under one year has shown a sensational 
decline in the last 60 years. This is not only due to more 
advanced medical standards but also to drugs of highest po-
tency. During the last 20 years when the drug industry made 
the greatest progress, the death rate of the under-one group, 
as well as the 75 to 84 age group had the greatest decline in 
the rate of death. The millions of dollars spent for research 
to discover new drugs for the very young and the very old 
have definitely paid off. 
During the last 40 years we have also seen an in-
crease in life expentancy. 
TABLE XIX 
LIFE EXPECTANCY IN THE U.S.A. 1920-1959 
YEAR EXPECTATION OF LIFE AT BIRTH 
1920 54.1 
1930 59.7 
1940 62.9 
1950 68.2 
1959 69.7 
Source: U. S. Department of Commerce, Statistical Ab-
stract of the U. S. A., {83rd Edition, No. 63, 
1962), p. 60. 
Table XIX shows that life expectancy increased from 54 to 
almost 70 years, during the 40 year period. These added 
years have contributed billions of dollars to the Gross Na-
tional Product since the productive years of the average per-
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son has been increased considerably. 
In summary, new drugs have disarmed within the 
last 20 years such killers as diphtheria by 100%; tuberculo-
sis by 91~ and syphilis by 8~. These gifts of life and health 
have come from the combined efforts of the health team. The 
pharmaceutical industry has played a great role in the fight 
against disease. 
PUBLIC BENEFITS OF THE COMPETITIVE SYSTEM 
IN THE DRUG INDUSTRY 
The drug industry has demonstrated to the public 
that it can operate quite well without government control. 
With more intense government control or even ownership of 
the industry, there is no reason to assume that cost of drugs 
should drop. Government ownership of various industries in 
Germany has not only led to increases in cost of operations, 
but also to inefficiency. Of a total of 540 single chemical 
entities which were introduced between 1941 and 1961 only 
one was reported from behind the Iron Curtain as compared to 
333 from the U. S. A. 
The competitive profit system in the drug industry 
will benefit the public in the following ways. 
(1) Best incentives for developing needed 
drugs. 
(2) Assured quality and reasonable safety of 
drugs. 
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(3) Prompt distribution of drugs and necessary 
information to the health team. 
(4) Outstanding foreign drug discoveries are 
made available quickly. 
Without the stimulating competition, freedom from unneeded 
regulation and deserved rewards for new drugs have made the 
United States drug industry the recognized world leader in 
drug discoveries. 
In the following chapter the author will discuss 
ways to lower cost of drugs. 
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CHAPTER VIII 
WAYS TO LOWER COST OF DRUGS. 
GENERIC NAME 
There are many ways to reduce the cost of drugs, 
but there is only one effective way to reach this goal: have 
doctors prescribe drugs by generic name instead of brand 
names. 
Senator Estes Kefauver realized the importance of 
generic name drugs when he proposed that generic names must 
appear in all advertising and labels in type at least half 
the size of the trade name. This, of course, is intended to 
make doctors remember generic names, but the author feels 
that sales of generic name drugs will not increase appreciably. 
GENERIC NAME DRUGS - A SOLUTION TO HIGH PRICES? 
What are generic name drugs? As each new drug is 
discovered, a generic name is chosen as the common name for 
the drug. This is required by federal law. A specific trade 
name drug is manufactured by only one company whereas its 
generic equivalent can be manufactured by any drug firm. 
When the physician, and only 10% of them do, prescribes a 
drug by generic name he will not know what manufacturer will 
supply the chemicals. However, by prescribing trade names 
there will generally be "consistent results and uniformly de-
pendable products of a reliable manufacturer."79 In Chapter 
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II the wide difference in product quality of small drug houses 
and drugs made by the large companies with rese~rch facili-
ties. In fact of the 1,200 companies doing 13% of the eth-
ical volume, nearly 6% of the samples examined were subject 
to legal action. This is 120 times greater than for drugs 
examined by the 28 leading companies doing 87% of the ethi-
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cal drug business. While many companies may make the same 
generic name drug, there can be wide differences as to "potency, 
sustained release medication, enteric coated tablets, tablet 
disintegration time, drug solubility, particle size, choice 
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of vehicle base and quantity of active ingredient." In an 
article published in Die Pharmazie, investigators found 
"therapeutic differences between the (PREDNISONE) two prod-
ucts of such magnitude that, when patients on product A were 
switched to product B the healing process stopped or was even 
81 
reversed." Such differences are due to factors listed 
above. 
REAL SAVINGS 
As noted, the single greatest apparent saving in 
drug costs would be to persuade doctors to prescribe by ge-
neric rather than by brand name. Advocates of this system 
talk of savings up to 50%. There is no doubt that patients 
can save that much, but if most drugs are prescribed by ge-
neric name, where will the incentives be for the research 
companies to invest money in new projects? If a company can 
not even recover its development costs, there is no sense in-
vesting in new projects. We have seen in Chapter II, Table 
I, page 10 that small drug houses that specialize in generic 
name drugs can underbid the large companies easily. The 
reason for the cost differential is that these coat-tail 
riders have no research and development expenditures. 
Bill Sl552 which was recently passed by Congress 
may increase sales of generic name drugs by a small percent-
age, because the generic name must appear at least one-half 
the size of the trade name on advertisements and labels, but 
it is the author•s belief that the trend toward trade name 
drugs (90% of all prescriptions called for today are in pre-
pared tablets as compared to 25% a decade ago) will not be 
reversed. 
DRUG PURCHASES ABROAD 
Although government purchases of ethical drugs 
amount only to 3% of total U. S. A. drug sales, almost every 
ethical drug company is interested in government contracts 
because of the relatively large size of the contracts and 
the lower packaging, handling, and distribution costs that 
will be incurred by making one large shipment. 
CONSIDERABLE SAVINGS 
In the last few years domestic drug firms have not 
received as many contracts as they had hoped for. Instead 
various agencies of the government went abroad to purchase 
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their drug requirements. This change can be attributed to 
"persistent refusal of the domestic drug companies to furnish 
cost data, in contrast to most other defense contractors, 
makes it impossible for the Department of Defense to assure 
fair pricing to the Government in drug purchases."82 In ad-
dition, Assistant Secretary Morris charged that "drug compa-
nies will charge the government what the •market will bear.•"83 
Tbe Medical Defense Supply Center, which makes all 
the drug purchases for the Armed Services, claims that it 
can save millions of dollars in taxpayer's money by buying 
drugs overseas. The following table will serve as an 
illustration. 
TABLE XX 
DEFENSE SUPPLY AGENCY PURCHASES OF DRUGS 
TOTAL $ TOTAL $ 
VALUE OF VALUE OF 
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NUMBER OF FOREIGN DOMESTIC $ SAVINGS 
PRODUCT CONTRACTS CONTRACTS CONTRACTS PER PRODUCT 
Tetracycline 14 $4,831,070 $ 9,023,026 $ 4,191,956 
Meprobamate 6 944,921 5,829,519 4,884,598 
Nitrofurantion 6 549,574 1,558,162 1,008,586 
Chloretetracycline 3 388,126 794,112 405,986 
Sulfadiazine 2 130~.842 267~.358 136,516 
,5,844)533 ,17,472,177 ~10,627,642 
Source: Military Operations Subcommittee, Staff Memo-
randum, Defense Procurement of Forei~n Made 
Drugs, (87th Congress, 2nd Session,ctober, 1962), 
p. 34. 
A 10 million dollar difference on five drugs alone demon-
strates the amount of money that can be saved by government 
agencies. The Veterans Administration, too, has gone over-
seas to buy tranquilizers. A Danish company offered "$3.84 
per bottle of 500 pills. The lowest price offered by Carter, 
the U. S. patent holder was $19.25."84 
OTHER FACTORS TO CONSIDER 
Such savings, as shown in Table XX, look quite im-
pressive. It must, however, be taken into consideration 
that the Veterans Administration will have to set up a spe-
cial inspection system overseas which will increase the cost 
of the drugs indirectly. In addition, the government, by 
buying drugs overseas, encourages piracy on part of foreign 
companies, especially in Italy and Denmark. As was pointed 
in a special report by U. S. News and World Report "instead 
of helping these companies (drug) stamp out theft, some Con-
gressmen say the government is buying some "'bootleg'" items 
at cut-rate prices."85 Since the foreign companies copy pat-
ented U. S. products and pay~ royalty for them, the pur-
chases by U. S. Government, therefore, infringe on the do-
mestic companies' patents. 
CUT-RATE STORES 
One way of reducing the cost of drugs for the con-
sumer is by establishing cut-rate stores. While this prac-
tice iS well established in the New York area, it has not yet 
gained force in many other parts of the country. 
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UNION PHARMACY 
In New York City the Medford Plan, Inc., a union 
pharmacy, has 350,000 members and offers drugs at a 30% 
savings. The plan was financed through a $1 contribution by 
each member. Apparently the system is working out quite well 
because more stores will be opened in the future. 
THE DISCOUNT PHARMACY 
Unlike the union pharmacy, the discount pharmacy 
is open to everyone. In Manhattan alone, at least 50% of 
all drugstores offer some discounts. The consumer by shop-
ping around for the lowest prescription price can save up to 
25% per prescription. People in outlying areas of New X.ork 
City are becoming aware of the savings and more and more of 
them travel to Manhattan to have their prescriptions filled. 
HOSPITAL FORMULARY 
There are always several trade names for a generic 
name drug. If a hospital carries all brand names of this 
particular drug, it would not only result in a large invest-
ment but also in some duplication. To avoid large invest-
ments and duplications of similar drugs, hospital formularies 
are used by a ever increasing number of hospitals. 
Some hospitals claim savings of up to 25% by switch-
ing to generic name drugs whenever possible and hold the num-
ber of brand name medicines to a ~nimua. There is very in-
tense competition among drug firms to get their product on 
the "formulary." When the product is not on the formulary, 
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it is very difficult to sell the particular product to the 
hospital pharmacy. 
The author feels that the system is an excellent 
way of reducing the overall cost of drugs, but is must also 
be remembered that a doctor has no choice of the various 
drugs that are available for the particular sickness. He 
must, generally speaking, use the drug on the formulary wheth-
er he wants to or not. 
DISCOUNTS FOR WELFARE PATIENTS 
Merck & Company, Inc. in 1961 initiated a system 
whereby they make a 10% refund to certain states for all pre-
scription expenditures they incurred for welfare patients. 
"California's check covering January (1961) came to $4,485.20; 
Florida's to more than $3,000. 1186 
It is the author's opinion that the system initiated 
by Merck will not only help financially the states involved, 
but the company too since Merck can expect to gain a lot of 
goodwill which, in turn, may express itself in increased 
business. 
LOWER DRUG COST -- SUMMARY 
In the preceding pages the author discussed several 
ways to lower the cost of drugs to the consumer. The most 
effective way is to ask doctors to prescribe drugs in terms 
of generic names. The patient is sure to save money assuming 
the druggist passes on the low bulk material prices to the 
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patient, but it must also be admitted that the quality of 
many generic name drugs that are made by small drug houses 
do not always meet the high standards of the trade name 
drugs. 
As far as drug purchases abroad are concerned, 
they will have no effect on retail drug prices in the United 
States. A consumer, however, can save up to 30% if he has 
his prescriptions filled in a cut-rate store. 
Most consumers are not aware of the various ways 
they can save on prescriptions. If consumer and labor 
unions would educate the public about the possible savings 
through some of the ways discussed in this chapter, they 
would do a real service to the public. 
In the following chapter an analysis will be made 
of the drug industries of several foreign countries. 
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CHAPTER IX 
DRUG PRICES IN OTHER COUNTRIES 
DRUG PRICES AND SOCIALIZED MEDICINE 
"The drug bill has continued to increase, so has 
the cost of individual prescriptions, and so have the indus-
try's profits. 1187 11The prices of some highly effective prep-
arations are four, five, and even six times the wholesale 
prices • .. BB 
The first quotation comes from the Comptroller and 
Auditor General of the United Kingdom. The second is from 
the Health Minister of the Soviet Union, Maria D. Kovrigina. 
These are only two of the many statements that can be pre-
sented in connection with the subject. One can therefore 
assume that high drug prices are a universal problem. 
PRICE CONTROL OF DRUGS 
In order to stop the rising tide of high drug 
prices, some countries specify what markup a wholesaler and 
retailer can charge. Belgium's new drug law allows "a whole-
saler markup of 12.5% of the manufacturer's price and the 
pharmacist may set a 30% markup of the retail price."89 How-
ever, "for new products growing out of research in Belgium, 
the manufacturer is allowed a five-year markup at a higher 
rate. u90 
Belgium has discovered only ~ of the 161 major 
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drugs on the world market today. It is therefore understand-
able that some form of incentive (higher markup for new drugs) 
be given to find new drugs. 
In the United Kingdom a so-called truce had been 
agreed upon between the Comptroller and Auditor General and 
drug makers. One of the agreements was that drug makers 
would not raise prices. Apparently the truce was not kept 
because prices as well as profits went up during the truce. 
According to the Economist, profits of drug makers are above 
those of the general industry average. 
A WAY OUT? 
The British Health Ministry, like the U. s. Veter-
ans Administration, went to Italy two years ago to buy won-
der drugs. Officials of the Health Ministry had saved mil-
lions of dollars by buying drugs from the Italian drug manu-
facturers. American companies in the United Kingdom in the 
meantime did not sit idle while they lost their business to 
the "pirates" in Italy. Four weeks ago (February, 1963) 
"the High Court of Justice (United Kingdom) has enjoined the 
British Health Ministry from buying cut-rate, unlicensed 
91 drugs." The author believes that a similar ruling might 
come in the United States in the future. United States drug 
firms, especially Chas. Pfizer, have indicated that they will 
go to court to enjoin government agencies from buying unli-
censed drugs overseas. 
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NATIONAL HEALTH PLANS 
Social security was first initiated in Germany 
under Bismarck in 1888, and has spread from one country to 
another ever since. Today most countries in the world have 
social security in one form or another. 
RUSSIA 
In Russia, 11drugs are given free in hospitals, but 
others prescribed outside the hospital must be purchased in 
a local drugstore. 1192 However, in the U. S. S. R. there is 
only ~preparation for each chemical composition and there 
are no brand names. When new drugs come on the market, a 
general announcement is made in the medical press. 
The state-owned drug industry, by the way, has not 
discovered a major drug in 44 years! 
AUSTRALIA 
Eighty per cent of the eleven million people in 
Australia are covered by the country's health program. The 
Commonwealth pays for certain drugs "life savings" (those 
absolutely necessary) but not for such things as tonics. Aus-
tralia's system, administered by its conservative government 
for eleven years, is considered less socialized than the sys-
tem in the United Kingdom because the patient has more free-
dom in regard to the choice of doctors. 
UNITED KINGDOM 
In the fiscal year 1958 - 1959, expenditures for 
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the health services by the National Health Service amounted 
to 696 million pounds whereas receipts amounted only to 149 
millionpounds. "Seventy-two per cent of the difference had 
to be met by the Exchequer. 11 93 As was seen in the previous 
page, there is a loud cry on the part of the Comptroller 
and Auditor General of the United Kingdom to decrease the 
price of drugs so that the Exchequer would not have to pay 
for such a large deficit. 
In the United Kingdom there is a one shilling (14 
cents) charge for each item prescribed; the actual cost is 
paid out of the National Health Service Fund. 
With the exception of Germany, the United Kingdom 
had the highest number (23) of drug discoveries between 1941-
1961 among countries with socialized medicine. 
ADVERTISING REGULATIONS 
In foreign countries firms do not advertise as 
heavily as in the United States. 
Medical practioners in France do not get the flood 
of free articles serving as advertising since pharmaceutical 
manufacturers "are not authorized to give free articles ser-
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ving advertising purposes." In Denmark and France "adver-
tising of medicines in the press is only permited if the ad-
vertising has been approved by the Health Department."95 
While United States drug manufacturers do not have 
to get prior approval for a new piece of advertising, the 
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Federal Trade Commission does keep a close eye on all adver-
tisements that appear in the lay, as well as in the medical, 
press. It would certainly be in the best interest of the 
public to have an even greater control over lay press adver-
tisements because sometimes drug firms, especially those in 
the proprietary field, knowingly place exaggerated claims 
into advertisements. By the time firms are forced to with-
draw the ad they have gotten enough "mileage" out of it. 
The new drug law passed recently tightens control 
over almost every segment of the drug industry. What will 
·.the new law mean in regard to drug prices and profits? An 
analysis of this question follows in the next chapter. 
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CHAPTER X 
THE FUTURE OF THE U.S. ETHICAL DRUG INDUSTRY 
DRUG INDUSTRY LEGISLATION 
The Senate on August 23, 1962 passed by a 78 to 0 
roll call vote the amended drug bill Sl552. 
The bill resulted in a tighter control over manu-
facturers; it will .increase the cost of making drugs, and 
will increase the time-span between the development and mar-
keting of new drugs. The Food and Drug Administration now 
has 180 days to act on a new drug; compare this with "15 
days in Peru and 4 weeks in Lebanon."96 Unlike previously,. 
the F. D. A. will now have enough time to evaluate and test 
new drugs. This will slow down the introduction of new 
products, but it will definitely be in the interest of con-
sumers since more tests might reveal a greater amount of 
positive as well as negative information about a drug. 
NEW PRODUCTS 
The Kefauver investigation, the new drug bill and 
unfortunate side effects of drugs on the market have slowed 
down the introduction of new drugs in 1962. Only "30 new 
drugs were introduced in 1962 as compared to 41 in 1961, 45 
in 1960 and 40 in 1958."97 While the slowdown will be very 
costly from the manufacturers' point of view, "the prescrip-
tion drug industry favored the idea that manufacturers should 
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present •substantial evidence~tu98 
RESEARCH 
The public will get an unexpected bonus from the 
new bill. Many manufacturers are putting new products 
through longer periods of research study, including labora-
tory and clinical trials. In addition more technical and 
supporting staff will be hired. This will increase the cost 
of research, which may sooner or later result in higher drug 
prices. Senator Kefauver had hoped to accomplish just the 
opposite. The author believes, however, that people may be 
willing to pay a few more cents per pill as long as they 
know they get effective and reasonably safe drugs. 
COMPETITION, PRICES, AND PROFITS 
A forecast by the Magazine of Wall Street lists 
three factors which will influence the profitability of the 
drug industry in the future. 
A. 11 Competition 
B. Price softness 
C. Readjustment arising from Kefauver invest-
igation still beset the industry. 1199 
Competition will increase for two reasons: (1) Increased 
research in the various drug groups. (2) As companies in-
troduce fewer new drugs, they tend to concentrate on existing 
products and promote them more heavily than before. 
Price softness in the drug industry can be demon-
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strated through the decrease in bulk material prices for 
vitamins and decrease in antibiotic prices. With increased 
competition in the various drug groups, we may see a further 
price softness in other pharmaceuticals. 
Several new products had to be withdrawn in 1962. 
This may hurt profits considerably because new products are 
the best source for high profits. Therefore, "over the long 
term, only a steady flow of new products will assure finan-
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cial growth." 
The three factors mentioned by the Magazine of Wall 
Street may also account for a slowdown in the growth rate of 
the industry in the future. During the 50's, the annual in-
dustry growth was about 10%; for the 60's the growth is es-
timated at 6% annually. Sales of foreign subsidiaries will 
greatly contribute to this growth rate; in fact "with per-
centage gain in foreign sales significantly outpacing that 
for domestic sales."101 But, "the fact must be accepted 
while the industry is still moving ahead, the period of most 
t 11102 rapid growth is probably in the pas • 
The factors that will create the fairly normal 
growth {6% annually) are population growth, untapped markets 
for new drugs and an aging population. Should the medical 
bill be passed by Congress, this would be an additional spur 
to drug sales because of the medical assistance which would 
be provided to the aged. 
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CONCLUSION 
During the past few years, the drug industry has 
been subjected to a variety of examinations by the courts, 
legislative groups, administrative agencies, and by citizen 
organizations. As a result of these examinations, the phar-
maceutical industry has been called monopolistic, profiteer-
ing and conspiratorial. 
These charges were made because ethical manufac-
turers have a higher rate of return no matter how returns 
are measured. Higher profits, however, do not necessarily 
mean that the industry or several companies are monopolistic 
or conspiratorial. Why? 
(1) The drug industry is a major growth in-
dustry. Its annual growth in the 50's was ~. This growth 
involved $1.7 billion in research expenditures and $670 mil-
lion in capital outlays from 1950 to 1961. To quote Presi-
dent Johh F. Kennedy "only by higher income and profits can 
we provide the incentive and means of increased investment."103 
The research expenditures seem unusually high, but: 
a. The drug industry employs 4.5 scien-
tifically trained men for every 1,000 other employees as com-
pared to 1.27/1,000 in the chemical industry. 
b. A growth industry requires heavy re-
search expenditures in order to discover new products and 
maintain the industry's growth rate. 
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c. Stiff competition forces pharmaceu-
tical firms to spend considerable sums for research so that 
they can keep in pace with market developments. 
d. Pharmaceutical research has produced 
new life-saving drugs that have revolutionized medical prac-
tice and helped to eliminate and shorten periods of hospital-
izations. 
(2) Adequate profits are the life-blood of 
the industry. Profits: 
a. Spark a human enterprise. 
b. Stimulate risky and uncertain under-
takings. Risk is twofold in the eth-
ical drug industry. 
1. Only one out of every 2,865 
compounds synthesized turns 
out to be a marketable drug. 
2. Heavy research expenditures 
often result in new prod-
ucts which make othersob-
solete. 
(3) Who can say how much profits are enough? 
There is no definite answer, rather rewards should balance 
risks. When it comes to risks, the ethical drug industry can 
claim its share. This is one reason why in 1961 the drug in-
dustryrs rate of return on sales was 10.5%; the overall in-
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dustry's return was ~. 
The 10.5% rate is an average for all companies in 
the pharmaceutical field. However, for the eleven leading 
firms the rate of return was 12.1%. In addition, companies 
that manufacture "wonder drugs" have an even higher rate of 
return. G. D. Searle had a 21% return on sales in 1961; 
Smith, Kline & French had a net profit of 17% on sales in 
1961. 
Using operating income as a percentage of sales, 
the drug industry is ahead of all other industries. Final-
ly, when profits are measured in terms of invested capital, 
the industry average for 1961 was 16.9%. This ranks the 
ethical industry highest of any industry. 
Profits are high no matter how they are measured, 
but the drug firms have used the higher profits wisely. 
Over $2.4 billion were re-invested into research and capital 
expenditures in the last eleven years. Out of these expend-
itures came the greatest discoveries ever made: antibiotics, 
tranquilizers, diuretics, etc. Many new drugs have cut down 
the length of hospitalization and that of prolonged illness. 
This, by itself, decreases the cost of sickness since the 
patient will save a lot of hospital expenses. In addition, 
he will be able to return to work earlier, thus earning in-
stead of losing money. 
Drugs have also slashed death rates from once-
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feared diseases; influenza and pneumonia death came down 68% 
in the last 30 years; the death rates from gastritis and 
colitis have decreased 83% between 1930 and 1960. 
Sixty-six per cent of all major drug discoveries 
in the world between 1941 to 1961 were made in the United 
States. Without adequate profits, the drug companies would 
not have been able to make such phenomenal discoveries. 
As far as competition is concerned, the 20 largest 
companies account for 68% of total ethical drug sales. Yet, 
not one single firm accounts for more than 10% of industry 
sales. There may have been a lack of competition in the 
tranquilizer field when Carter Products, Inc. had exclusive 
control over the market, but Carter not only has been forced 
by the courts to grant licenses to any qualified company 
starting now (March, 1963), but other companies have come 
out with chemically different tranquilizers that compete 
effectively with Carters' tranquilizer. In all the other 
drug groups, the author has found a lot of competition. 
The United States patent system has often been 
blamed for high profits. In the author's opinion the system 
is vital for the continuous growth of the industry. Without 
the patent protection, there may be a lack of incentive to 
invest more money for research. 
In summary, drug profits are admittedly higher than 
average, but profits are an essential factor for both economic 
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growth and for social usefulness; using both of these criteria 
to make an evaluation, the drug industry has an outstanding 
record. Moreover, above average profits are necessitated 
by: 
(1) Unusually large research expenditures. 
(2) High capital requirements. 
(3) Exceptionally high risks. 
No profits equal no capital, no capital equals no 
drugs, no drugs equal no jobs! 
141 
(1) 
(2) 
(3) 
(4) 
(5) 
{6) 
(7) 
(8) 
LIST OF FOOTNOTES 
"Drug Industry •• Filling Prescriptions Under Fire," 
Business Week, (No. 1632; December 10, 1960), p. 141. 
Congressional Quarterly Inc., Co ressional Quarterl 
Almanac, The Authorative Reference on Congress, XVI; Congressional Quarterly Inc., August 27, 19 
p. 743. 
Mark Merrell, E. T. Grether, Summer S. Kittelle, 
U. S. Recovery Administration, {Work Material No. 57; 
Trade Practice Studies Section, March, 1939), p. 1. 
Jules Blackman, Economics of the Drug Industry, An 
Address Before the Pharmaceutical Manufacturers 
Association at Boca Raton, {Florida: April 6, 1960), 
p. 11. 
Morris A. Bealle, The New Drug Story, {Washington, 
D. C.: Columbia Publishing Company), p. 173. 
Ibid • , p. 167. 
Congressional Quarterly Inc., Co ressional uarterl 
Almanca, The Authorative Reverence on Congress Vol. 
XVI; Congressional Quarterly Inc., August 27, 1960), 
p. 745. 
Williams. Merrell Company, Salesman Instruction Man-
ual, (Serial No. 65; Cincinnati, Ohio), p. 1. 
(9) "Drug Industry •• Filling Prescriptions Under Fire," 
Business Week, (No. 1632; December 10, 1960), p. 146. 
{10) 
(11) 
(12) 
Health News Institute, Facts About Pharmacy and 
Pharmaceutical, {New York), p. ll. 
Thompson & McKinnon Investment Survey, (New York: 
Thompson & McKinnon Company, Inc., March 1, 1961), p.2. 
American Medical Association, Today's Health, (Vol. 
XL; No. 8, American Medical Association, August, 1962), 
p. 51. 
(13) "The Wayward Drug Industry •• A Study in Profiteering," 
The American Federationist, (Vol. XLVIII; No. 12, 
December, 1961), p. 12. 
142 
(14) Morris A. Bealle, The New Drug Story, {Washington, 
D. C.: Columbia Publishing Company), p. 181. 
(15) "Drug Trade," The Encyclopedia Americana, {Vol. IX; 
New York- Chicago -Washington, D. C.: Americana 
Corporation), p. 345-346. 
{16) 
(17) 
{18) 
(19) 
(20) 
(21) 
(22) 
(23) 
(24) 
(25) 
{26) 
Ibid. 
William S. Merrell Company, Salesman's Instruction 
Manual, (Serial No. 65; Cincinnati, Ohio), p. 2. 
"Drug Industry •• Filling Prescriptions Under Fire," 
Business Week, {No. 1632; December 10, 1960), p. 145. 
Ibid. 
National Pharmaceutical Council, Misconceptions About 
So-Called "Generic Equivalent" Drugs{ (New York: 
National Pharmaceutical Council Inc.J, p. 7. 
Leonard Larson, "Higher Cost of Better Medicine •• How 
Should It Be Paid For," Time Magazine, (Vol. LXXVIII; 
No. 1, July 7, 1961), p. 59. 
Standard and Poors, "Drugs, Basic Analysis," Drugs, 
Cosmetics, (December 13, 1962, Section 2, Discard 
Basic Analysis dated November 30, 1960), p. D-20. 
(Figures were compiled by the author from this study) 
Pharmaceutical Manufacturers Association, Questions 
and Answers on the Cost of Drugs, (Washington, D. C.: 
Pharmaceutical Manufacturers Association) p. 7. 
American Medical Association, The American Medical 
Association News{ (American Medical Association, 
January 21, 1963J, p. 1. 
Pharmaceutical Manufacturers Association, Safety of 
Prescription Drugs, (Washington: Pharmaceutical 
Manufacturers Association), p. 2. 
"Drug Industry •• Filling Prescriptions Under Fire," 
Business Week, (No. 1632; Decemb~r 10, 1960), p. 148. 
143 
(27) 
(28) 
(29) 
(30) 
(31) 
(32) 
(33) 
(34) 
(35) 
Pharmaceutical Manufacturers Association, The Better 
Life, A Chart Story of Drugs and the Drug Industry 
(Washington, D. C.: Pharmaceutical Manufacturers 
Association, 1961), p. 25. 
Hubert D. Henderson, Supply and Demand, (New York: 
Harcourt, Brace & Company, Inc., 1922), p. 37-40. 
Industrial Union Department, AFL-CIO, Pill, Prescrip-
tions and Profits, (Publication No. 41; Washington, 
D. C.: Industrial Union Department, AFL-CIO), p. 11. 
"Health Spending Increases," Medical News Magazine, 
(Vol. VII; No. 1, January, 1963), p. 83. 
U. S. Department of Commerce, Survet of Current Busi-
ness, Office of Business EconomicsVol. XLII; No. 12, 
December, 1962), p. S-7. 
Claude Robinson, Understanding Profits, (Princetown, 
New Jersey: Van Nostrand Company, Inc., 1961), 
p. 46-47. 
Business Week, (No. 1702; April 14, 1962), p. 51. 
"Attack on Profits," The Conmercial and Financial 
Chronicle, (Vol. CXCIV; October 12, 1961), p. 9. 
Sewell F. Bray, The Measurement of Profit, (London: 
Geoffrey Cumberlege, Oxford University Press, 1949), 
p. 37. 
(36) "Drug Industry Investigation," Congressional Quarterly 
Almanac, (Vol. XVII; 1961), p. 290. 
(37) "Who Sets Prices In Industry," Business Week, (No. 1536; 
July 5, 1958), p. 48. 
(38) "Drug Industry Investigation," Congressional Quarterly 
Almanac, (Vol. XVI; 1960), p. 743. 
(39) 
(40) 
(41) 
Dru~ and Cosmetic Industry, (Vol. XCII; No. 1, January, 
196 ), p. l5. 
E. F. Hutton & Co., Inc., Standard and Poors• Stock 
Guide, (No volume number given; February, 1963), 
p. 1-225. 
Ibid., p. 239-251. 
144 
(42) 
(43) 
(44) 
(45) 
(46) 
(47) 
(48) 
(49) 
"Standard Corporation Descriptions," Standard & Poors, 
(Vol. XXIII; No. 22, Section 2, September, 1962), 
p. 4051-4052. 
"Investment Survey," The Value Line, Ratings and Report 
Section, (Vol. XVIII; No. 5, November 26, 1962), 
p. 587. 
David L. Babson & Company, The Widely Misunderstanding 
of Profits, Weekly Staff Letter, {David L. Babson & 
Company, March 12, 1962), p. 1. 
Lionel D. Edie & Company, Inc., The Profitability of 
Industry, (Lionel D. Edie & Company, Inc., November, 
1962}, p. 1. 
Chamber of Commerce of the U. S. A., Profits, Something 
For Ever one, Report of the Committee on Economic 
Policy. No volume number and date given) 
The Industrial Relations Center, P~ofits at Work, 
Basic Economics, {The Industrial Relations Center, 
The University of Chicago, 1961), p. 21. 
E. I. Du Pont De Memours & Company, "The Profit 
Motive," This is DuPont, {E. I. DuPont De Memours & 
Company, 1962), p. 26. 
A. C. Nielsen Company, Review of Retail Drug and 
Proprietary Store Trends, (Nielsen & Company, 27th 
Annual Nielsen Review, 1961), p. 11. 
(50) "The Wayward Drug Industry: A Study in Profiteering," 
The American Federationist, (Vol. LXVIII; No. 12, 
December, 1961}, p. 12. 
(51) 
(52) 
(53) 
RX Health, Inc., Health A Grams, RX Health, (Vol. II; 
No. 1, RX Health, Inc., January, 1963), p. 3. 
U. S. Department of Labor, Medical Care: Aver~e 
Retail Prices, U. S. Bureau of Labor Statistics, {1960), no page number. 
of New York, Inc., 
Im act on the Famil 
145 
(54) 
(55) 
(56) 
(57) 
(58) 
(59) 
(60) 
Firat National City Bank of New York, "Business and 
Economics Conditions," Financing Growth, (Monthly 
Letter, June, 1962), p. 70. 
General Electric Company, The Chairman's Comments, 
(1961 Annual Report), p. 1. 
Pharmaceutical Manufacturers Association, "High 
Capital Requirements," Prescriptions, Profits and 
Progress, (Pharmaceutical Manufacturers Association}, 
p. 7. (No volume number or date given) · 
Standard & Poors, "Basic Analysis," Drue;s, Cosmetics, 
(Section 2, December 13, 1962, Standard & Poors 1 
Industry Surveys), p. D-10. 
"1963 Outlook Varies For Major Industries," The 
Magazine of Wall Street and Business Analys~(The 
Ticker Publishing Company, Vol. III; No. 9, January 
12, 1963), p. 446. 
Chamber of Commerce of the U. S. A., Profits, Something 
For Everyone, (No volume number or date given), p. 29. 
Standard & Poors, "Basic Analysis," Drugs, Cosmetic, 
(Standard & Poors, December 13, 1962), p. D-10. 
(61) "Drug Industry Research," Oil£ Paint & Drug Reporter, 
(Vol. CLXXVIII; No. 5, Augus 1, 1960), p. 31. 
(62) The Commercial Financial Chronicle, Drug Industry 
Research, (Vol. CXCIII; February 9, 1961), p. 13. 
(63) "Laws Alone Can't Make Drugs Safe," Fortune, (Vol. 
XVII; No. 3, March, 1963), p. 156. 
(64) Medical Economics, Inc., "Drugs, Chemical and 
Pharmacological Index," Physicians' Desk Reference, 
1963 (Medical Economics, Inc.), p. 209. 
(65) "News In Brief," Wall Street Journal, (February 5, 
1963), p. 1. . 
(66) 
(67) 
"Facts and Fancy on Identical Bids," Harvard Business 
Review, (Vol XLI; No. l, January~February, 1963), p. 67. 
"Patent Protection Is Not A Luxury," Reader's Digest, 
(Vol. LXXIX; No. 476, Reader's Digest Assoc., Inc., 
December , 1961), p. 72. 
146 
{68) "Filling Prescriptions Under Fire," Business Week, 
Special Report, (No. 1632; December 10, 1960), p. 141. 
{69) 11Guarding Patent," Chemical Week, (Vol. XCII; No. 6, 
February 9, 1963), p. 24. 
(70) 
(71) 
(72) 
(73) 
{74) 
(75) 
David c. Coyle, How To Get Safe Dpugs and Cut Their 
Costs, (Washington, D. C.: Public Affairs Institute), 
p. 2. 
Mark Merrell, E. T. Grether, Summer s. Kittelle, U. S. 
Recovery Administration, {Work Material No. 57; ·Trade 
Practice Studies Section, March, 1939), p. ·8. 
E. L. Newcomb, Fair, E uitable and Lawful Distribution, 
{New York: National Wholesale Druggist Association , 
p. 9. 
Industrial Union De~artment, AFL-CIO, Pill, Prescrip-
tions and Profits, lNo. 41), p. 16. 
{No publication or year given) 
Federal Trade Commission, Economic Report On Antibio-
tics, {Washington: U. S. Government Printing Office, 
June, 1958), p. 17. 
(76) A. C. Review of Retail 
No volume number 
(77) "Drug Prices," Business Week, (No. 1650; April 15, 
1961), p • 54 • 
(78) 
(79) 
{80) 
U. S. Department of Commerce, Bureau of the Census, 
"Industrial and Commercial Failures," Statistical 
Abstract of the U. S. A., {83rd Edition, 1962), p. 505. 
National Pharmaceutical Council, Inc., The Importance 
of Pharmaceutical Know-How, (No volume number given; 
no year given), p. 4-14. 
147 
(81) 
(82) 
(83) 
(84) 
(85) 
Smith, Kline & French Laboratories, Commentary, Are 
Equivalents Really Equivalent? (Philadelphia: ---
November, 1961), p. 3. 
Ibid. 
"Drug Industry:Filling Prescription Under Fire," 
Special Report, Business Week, (No. 1632; December 
10, 1960), p. 148. 
"Piracy-A Rising Worry For U. S. Business," Special 
Report, U. S. News & World Report, {Vol. LIII; No. 10, 
September 3, 1962), p. 83. 
(86) "Drug Prices," Business Week, (No. 1650; April 15, 
1961), p • 52. 
(87) "Drug Prices:End of the Truce," The Economist, (Vol. 
CXCIV; No. 6076, February 6, 1960), p. 548. 
(88) 
(89) 
(90) 
Raymond Bauer and Mark Field, "u. s. Vs. U. s. s. R., 
Harvard Business Review, (September - October, 1962), 
p. 89. 
"Foreign Government Action," Foreign Commerce Weekly, 
(August 14, 1961), p. 12. 
Ibid. 
(91) "No More Cut-Rate Drugs For British Health Ministry " 
Medical World New~, (Vol. IV; No. 5, March 1, 1963~, 
p. 18 0 
(92) 
(93) 
(94) 
(95) 
The Milbank Memorial Fund Quarterly, {Vol. XI; No. 4, 
October, 1962), p. 377. 
British Information Service, Health Service In Britain, 
(March, 1960), p. 46. 
International Digest of Health Legislation, Pharmaceu-
tical Advertising, (Vol. I; 1961), p. 21. 
Ibid., p. 19 • 
148 
(96) 
(97) 
(98) 
(99) 
(100) 
(101) 
(102) 
(103) 
International Digest of Health Legislation, (World 
Health Organization, Geneva, Switzerland, Vol. XIII, 
No. 3, 1962), p. 389. 
"Decline in New Drugs, 11 The AMA News, The Newspaper 
of American Medicine, (American Medical Association, 
January 21, 1963), p. 1. 
Medical World News, The Newsmagazine of Medicine, 
(Vol. III; No. 19, Medical World Publication Company, 
September 14, 1962~, p. 51. 
Ibid., p. 34. 
Standard & Poors, "Basic Analysis, 11 Drugs, Cosmetics, 
Industry Survey, (December 20, 1962), p. D-1. 
The Magazine of Wall Street and Business Analyst, 
(Vol. CX; No4 2, Ticker Publishing Company, April 7, 1962) J p. 5 • 
John F. Kennedy, "Address To A Luncheon Meeting of 
the National Industrial Conference Board," 
Cob!ressional Quarterly Weekly Report, (February 17, 
19 ) , p. 292. 
149 
BIBLIOGRAPHY 
PUBLIC DOCUMENTS 
Federal Trade Commission. Economic Report On Antibiotics. 
June, 1958. 
Federal Trade Commission-Securities and Exchange Commission. 
Quarterly Financial Reports For Manufacturing 
Corporation. 1956 - 1961. 
Military Operations Subcommittee. Defense Procurement of 
Foreign Made Drugs. 87th Congress, 2nd Session, 
October, 1962. 
Statistical Abstract of the u. s. A. Industrial and 
Commercial Failures. 82nd Annual Edition, No. 665, 
1961. 
u. S. Department of Commerce, Bureau of the Census. 
Industrial and Commercial Failures. 83rd Edition, 
1962. 
U. S. Department of Commerce, Survey of Current Business. 
Consumer Price Index. Vol. XLII; No. 12, 
December, 1962. 
U. S. Department of Labor, Bureau of Labor Statistics. 
u. s. 
Medical Care: Average Retail Prices. 1960. 
President, 1961-Present (Kennedy). 
Luncheon Meeting of the National 
Conference Board. Congressional 
Report, February 17, 1961. 
BOOKS 
Address To A 
Industrial 
Quarterly Weekly 
Bealle, M. A. The New Drug Story. Washington, D. C.: 
Columbia Publishing Company. 
Bray, S. F. The Measurement of Profit. London: Oxford 
University Press, 1949. 
Henderson, H. D. Supply and Demand. New York: Harcourt, 
Brace & Company, Inc., 1922. 
150 
Physicians• Desk Rererence. Oradell, New Jersey: Medical 
Economics, Inc., 1963. 
Robinson, C. Understanding Prorits. Princetown: Van 
Nostrand Company, Inc., 1961. 
The Encylopedia Americana. Vol. IX; New York, Chicago, 
and Washington, D. C. 
ARTICLES AND PERIODICALS 
American Medical Association. The American Medical 
. Association News, American Medical Association, 
(January 21, 1963), p. 1. 
American Medical Association. Today's Health,Vol. XL, No. 8, 
American Medical Association, (August, 1962), p. 51. 
Anderson, Odin W., Collette, Patricia, & Feldman, Jacob J. 
Family Expenditure Patterns For Periodic Health 
Services, (National Survey - 1953 & 1958), Health 
Information Foundation, p. 7. 
"Attack On Profits," The Commercial and Financial Chronicle, 
Vol. CXCIV; (October 12, 1961}, p. 9. 
Babson, David L. The Widely Misunderstanding of Profits, 
Weekly Staff Letter, David L. Babson & Company, 
(March 12, 1962), p. 1. 
Bauer, Raymond, and Field, Mark. "u. S. Vs. U. s. s. R.," 
Harvard Business Review, (September - October, 1962), 
p. 89. 
British Inrormation Service. Health Service in Britain, 
(March, 1960), p. 46. 
Business Week. 1950 - March, 1963. 
Chamber of Commerce of the U. s. A. Profits, Something For 
Everyone, Report of the Committee on Economic Policy. 
Congressional Quarterly Almanac. 1959 - 1961 {Vol. XV- XVII). 
151 
Coyle, David c. How To Get Safe Drugs and Cut Their Costs, 
Washington, D. C.: Public Affairs Institute, p. 2. 
"Decline in New Drugs," The AMA News, The Newspaper of 
American Medicine{ American Medical Association, 
(January 21, 1963), p. 1. 
"Drug and Toiletry Study," This Week Magazine, (8th Biennial, 
1960), p. 25. 
"Drug Industry Research.," Oil, Paint & Drug Reporter., Vol. 
CLXXVIII; No. 5, (August 1, 1960), p. 31. 
"Drug Prices: End of the Truce," The Economist, Vol. CXCIV; 
No. 6076, (February 6, 1960), p. 548. 
Edie, Lionel D. The Profitability of Industrl, Lionel D. 
Edie & Company, Inc., (November, 1962 , p. 1. 
"Facts and Fancy on Identical Bids~" Harvard Business 
Review, Vol. XLI; No. 1, \January-February, 1963), 
p. 67. 
First National City Bank of New York. "Business and 
Economics Conditions," Financing Growth, Monthly 
Letter, (June, 1962), p. 70. 
"Foreign Government Action," Foreign Commerce Weekly, 
(August 14, 1961), p. 12. 
General Electric Company. The Chairman's Comments, 
(1961 Annual Report), p. 1. 
"Guardi~ Patent," Chemical Week, Vol. XCII; No. 6, 
lFebruary 9, 1963), p. 24. 
Health News Institute., Facts About Pharmacy and Pharma-
ceutical, (New York), p. 11. 
"Health Spendi~ Increases," Medical News Magazine, Vol. VII; 
No. 1, lJanuary, 1963), p. 83. 
Hecker, F. C. The Lilly Digest 1961, (30th Annual Edition, 
Copyright 1962), p. 48. 
Industrial Union Department, AFL-CIO. Pill, Prescriptions 
and Profits, Publication No. 41, Washington, D. C.: 
Industrial Union Department, AFL-CIO, p. 11. 
l.52 
International Digest of Health Legislation. Pharmaceutical 
Advertising, Vol. I; (1961), p. 21. 
"Investment Survey, 11 The Value Line, Vol. XVIII; No. 5, 
(November 26, 1962), p. 587. 
Larson, Leonard. 11Higher Cost of Better Medicine .• How 
Should It Be Paid For," Time Magazine, Vol. LXXVIII; 
No. 1, (July 7, 1961), p. 59. 
"Laws Alone Can't Make Drugs Safe," Fortune, Vol. XVII; 
No. 3, (March, 1963), p. 156. 
Medical World News, The Newsmagazine of Medicine, Vol. III; 
No .. 19, Medical World Publication Company, (September 
14, 1962), p. 51. 
Moody's Stock Survey, Vol. LIV; No. 51, (December 17, 1962), 
p. 263. 
National Pharmaceutical Council. Misconceptions About 
So-Called "Generic Equivalent" Dr~s, New York: 
National Pharmaceutical Council, nc., p. 4 & 1. 
National Pharmaceutical Council. The Importance of 
PharmAceutical Know-How, New York: National 
Pharmaceutical Council, Inc., p. 4-14. 
Newcomb, E. L. Fairt Equitable and Lawful Distribution, 
New York: Na ional Wholesale Druggist Association, 
p. 9. 
"News In Brief, 11 Wall Street Journal, (February 5, 1963), 
p. 1. 
Nielsen, A. C. Review of Retail Drug and Proprietary Store 
Trends, Nielsen & Company, 27th Annual Nielsen 
Review, (1961), p. 11. 
Nielsen, A. C. 25th Annual Review of Retail Drug and 
Proprietary Store Trends, Nielsen & Company, 
Copyright 1959, p. 26. 
"No More Cut-Rate Drugs For British Health Ministry~" Medical 
World News, Vol. IV; No. 5, (March 1, 1963J, p. 18. 
"Patent Protection Is Not a Luxury," Reader's Digest, 
Vol. LXXIX; No. 476, Reader's Digest Assoc., Inc., 
(December, 1961), p. 72. 
153 
Pharmaceutical Manufacturers Association. "High Capital 
Requirements," Prescriptions, Profits and Progress, 
Pharmaceutical Manufacturers Association, p. 7. 
Pharmaceutical Manufacturers Association. Safety of 
Prescription Drugs, Washington: Pharmaceutical 
Manufacturers Association, p. 2. 
Pharmaceutical Manufacturers Association. Questions and 
Answers On the Cost of Drugs,, Washington: 
Pharmaceutical Manufacturers Association, p. 7. 
Pharmaceutical Manufacturers Association. The Better Life, 
A Chart Story of Drugs and the Drug Industry, 
Washi~ton: Pharmaceutical Manufacturers Associa-
tion, ll961), p. 25. 
"Piracy-A Rising Worry For u. S. Business," u .. s. News & 
World Report, Vol. LIII; No. 10, {September 3, 1962), 
p. 83. 
RX Health, Inc. Health A Grams, Vol. II; No. 1, RX Health, 
Inc., (January, 1963), p. 3. 
Smith, Kline & French Laboratories. Are Equivalents Really 
Equivalent? Philadelphia; {November, 1961), p. 3. 
Standard and Poors. "Drugs, Basic Analysis, 11 D6~s, 
Cosmetics, Section 2, {December 13, 19 2 , 
p. D-10 & D-20. 
Standard and Poors. "Basic Analysis," Drugs, Cosmetics, 
(December 20, 1962), p. D-1 
"Standard Corporation Descriptions," Standard & Poors, 
Vol. XXIII; No. 22, Section 2, (September, 1962), 
p. 4051-4052. 
The Industrial Relations Center. Profits at Work, 
The Industrial Relations Center, The University of 
Chicago, (1961), p. 21. 
The M 
The Milbank Memorial Fund Quarterly, Vol. XI; No. 4, 
(October, 1962), p. 377. 
154 
"The Wayward Drug Industry •• A Study in Profiteering, 11 
The American Federationist, Vol. XLVIII; No. 12, 
{December, 1961), p. 12. 
Thom son & McKinnon Investment Surve , New York: Thompson 
& McKinnon ompany, Inc., arch 1, 1961), p. 2. 
Wharton School of Finance. "Detailed Family Expenditures 
For Medical Care, 11 Study of Consumer Expenditures, 
Incomes and ~avings, Urban U. S. A., 1950, Vol. XVI; 
Wharton School of Finance and Commerce, University 
of Pennsylvania, (1957), p. 45. 
155 
